CUMULATIVE SUPPLEMENT 6
JAN'97-JUN'97

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DATABASE MANAGEMENT

Prepared By
Division of Database Management
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Cumulative Supplement 6

JUNE 1997

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

CUMULATIVE SUPPLEMENT 6
JUNE 1997

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 17th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 17th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 18th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA has published a notice in the March 14, 1997, *Federal Register* advising NDA and NADA

applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 17th Edition that explains the background information on this court decision).

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne PLSN [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP (CIBA GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP PHARMACEUTICALS DIV (CIBA GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
CIBA PHARMACEUTICAL CO DIV CIBA GEIGY CORP (CIBA)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
CIBA SELF MEDICATION INC DIV CIBA GEIGY CORP (CIBA)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
CIBA VISION OPHTHALMICS DIV CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
FERRING LABORATORIES INC (FERRING)	FERRING PHARMACEUTICALS INC (FERRING)
GEIGY PHARMACEUTICALS DIV CIBA GEIGY CORP (GEIGY)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
LEMMON CO SUB TAG PHARMACEUTICAL INC (LEMMON)	BIOCRAFT LABORATORIES INC (BIOCRAFT) **THEN CHANGED TO** TEVA PHARMACEUTICALS USA (TEVA)
SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS (SANDOZ)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
SANDOZ PHARMACEUTICALS CORP DIV SANDOZ INC (SANDOZ)	NOVARTIS PHARMACEUTICALS CORP (NOVARTIS)
SANDOZ RESEARCH INSTITUTE INC (SANDOZ)	NOVARTIS PHARMACEUTCALS CORP (NOVARTIS)
SANOFI WINTHROP INC (SANOFI WINTHROP)	SANOFI PHARMACEUTICAL INC (SANOFI)
SURVIVAL TECHNOLOGY INC (SURVIVAL TECH)	MERIDIAN MEDICAL TECHNOLOGIES INC (MERIDIAN MEDCL TECHN)

1.4 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novapharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; Prescription and OTC Drug Product Patent and Exclusivity Data; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaced the Agency's electronic bulletin board. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1996) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1996*	MAR 1997	JUN 1997	SEP 1997
DRUG PRODUCTS LISTED	9392	9493	9533	
SINGLE SOURCE	2383 (25.4%)	2387 (25.1%)	2388 (25.0%)	
MULTISOURCE	6905 (73.5%)	6991 (73.7%)	7031 (73.8%)	
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)	6549 (69.0%)	6626 (69.5%)	
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)	442 (4.7%)	405 (4.3%)	
EXCEPTIONS[1]	104 (1.1%)	115 (1.2%)	114 (1.2%)	
NEW MOLECULAR ENTITIES APPROVED	--	6	8	
NUMBER OF APPLICANTS	650	662	682	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions were no longer included in the Multisource Drug Products total count, but included in the total count of the Drug Products Listed.

ACARBOSE

TABLET; ORAL
PRECOSE
BAYER 25MG N20482 004 MAY 29, 1997

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN, CAFFEINE

AB	GRAHAM DM	325MG;50MG;40MG	N88743 001	JUL 18, 1985
AB		325MG;50MG;40MG	N88765 001	MAR 27, 1985
AB		325MG;50MG;40MG	N89067 001	APR 19, 1985
	@	325MG;50MG;40MG	N88743 001	JUL 18, 1985
	@	325MG;50MG;40MG	N88765 001	MAR 27, 1985
	@	325MG;50MG;40MG	N89067 001	APR 19, 1985

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	EON	500MG;5MG	N40149 001	JAN 27, 1997
AA		750MG;7.5MG	N40149 002	JAN 27, 1997
AA	VINTAGE PHARMS	500MG;2.5MG	N40144 002	APR 25, 1997
AA		650MG;7.5MG	N40155 001	APR 14, 1997
AA	WATSON LABS	500MG;10MG	N40148 002	FEB 14, 1997

LORTAB

AA	+ GRAHAM DM	500MG;10MG	N40100 001	JAN 26, 1996
AA	+ UCB	500MG;10MG	N40100 001	JAN 26, 1996
>ADD< >ADD<		325MG;5MG	N40099 001	JUN 25, 1997

NORCO

+	WATSON LABS	325MG;10MG	N40148 001 FEB 14, 1997

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	VINTAGE PHARMS	650MG;100MG	N74843 001	FEB 12, 1997

ACETAZOLAMIDE

TABLET; ORAL
ACETAZOLAMIDE

AB	TARO	125MG	N40195 001	MAY 28, 1997
AB		250MG	N40195 002	MAY 28, 1997

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC
TRIDESILON

	BAYER	2%;0.05%	N17914 001
	@	2%;0.05%	N17914 001

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	AESGEN	200MG	N74833 001	APR 22, 1997
AB	ESI LEDERLE	200MG	N74872 001	APR 22, 1997
AB	LEK PHARM	200MG	N74750 001	APR 22, 1997
AB	LEMMON	200MG	N74828 001	APR 22, 1997
AB	MYLAN	200MG	N74727 001	APR 22, 1997
AB	NOVOPHARM	200MG	N74578 001	APR 22, 1997
AB	ROXANE	200MG	N74570 002	APR 22, 1997
AB	TEVA	200MG	N74828 001	APR 22, 1997
AB	ZENITH GOLDLINE	200MG	N74674 001	APR 22, 1997

>DLT< >DLT<
>ADD< >ADD<

ACYCLOVIR

CAPSULE; ORAL

		ZOVIRAX		
AB	+	GLAXO WELLCOME	200MG	N18828 001 JAN 25, 1985

SUSPENSION; ORAL

		ACYCLOVIR		
AB		ALPHARMA	200MG/5ML	N74738 001 APR 28, 1997
		ZOVIRAX		
AB	+	GLAXO WELLCOME	200MG/5ML	N19909 001 DEC 22, 1989

TABLET; ORAL

		ACYCLOVIR		
AB		ESI LEDERLE	400MG	N74834 001 APR 24, 1997
AB			800MG	N74834 002 APR 24, 1997
AB		LEK PHARM	400MG	N74658 001 APR 22, 1997
AB			800MG	N74658 002 APR 22, 1997
AB		NOVOPHARM	400MG	N74556 002 APR 22, 1997
AB			800MG	N74556 003 APR 22, 1997
	+		200MG	N74556 001 APR 22, 1997
> ADD >	AB	PUREPAC PHARM	400MG	N74870 001 JUN 05, 1997
> ADD >	AB		800MG	N74870 002 JUN 05, 1997
> ADD >	AB	ZENITH GOLDLINE	400MG	N74836 001 APR 22, 1997
	AB		800MG	N74836 002 APR 22, 1997
		ZOVIRAX		
	AB	GLAXO WELLCOME	400MG	N20089 001 APR 30, 1991
	AB +		800MG	N20089 002 APR 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

		ACYCLOVIR SODIUM		
AP		ABBOTT	EQ 500MG BASE/VIAL	N74758 001 APR 22, 1997
AP			EQ 1GM BASE/VIAL	N74758 002 APR 22, 1997
AP		BEDFORD	EQ 500MG BASE/VIAL	N74596 002 APR 22, 1997
AP			EQ 1GM BASE/VIAL	N74596 001 APR 22, 1997
	+	FAULDING	EQ 25MG BASE/ML	N74720 001 APR 22, 1997
AP		SANOFI WINTHROP	EQ 500MG BASE/VIAL	N74663 001 APR 22, 1997
AP			EQ 1GM BASE/VIAL	N74663 002 APR 22, 1997
		ZOVIRAX		
AP	+	GLAXO WELLCOME	EQ 500MG BASE/VIAL	N18603 001 OCT 22, 1982
AP	+		EQ 1GM BASE/VIAL	N18603 002 JUN 29, 1989

ALENDRONATE SODIUM

TABLET; ORAL

		FOSAMAX		
		MERCK	EQ 5MG BASE	N20560 003 APR 25, 1997

ALPRAZOLAM

TABLET; ORAL

		ALPRAZOLAM		
AB		ROYCE LABS	0.25MG	N74479 001 JAN 21, 1997
AB			0.5MG	N74479 002 JAN 21, 1997
AB			1MG	N74479 003 JAN 21, 1997

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

> ADD >	**AP**		PHARMACIA AND UPJOHN	**0.005MG/VIAL**	**N20379 003**
> ADD >					JUN 27, 1996
> ADD >	**AP**			**0.01MG/VIAL**	**N20379 001**
> ADD >					JUL 06, 1995
> ADD >	**AP**			**0.02MG/VIAL**	**N20379 002**
> ADD >					JUL 06, 1995
> ADD >	**AP**	+		**0.04MG/VIAL**	**N20379 004**
> ADD >					MAY 19, 1997

EDEX

> ADD >	**AP**		SCHWARZ PHARMA	**0.005MG/VIAL**	**N20649 001**
> ADD >					JUN 12, 1997
> ADD >	**AP**			**0.01MG/VIAL**	**N20649 002**
> ADD >					JUN 12, 1997
> ADD >	**AP**			**0.02MG/VIAL**	**N20649 003**
> ADD >					JUN 12, 1997
> ADD >	**AP**	+		**0.04MG/VIAL**	**N20649 004**
> ADD >					JUN 12, 1997

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP		ELKINS SINN	**EQ 50MG BASE/ML**	**N63274 001**
				MAY 18, 1992
	@		EQ 50MG BASE/ML	N63274 001
				MAY 18, 1992

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	ABBOTT	EQ 500MG BASE/100ML	N64146 001
			APR 02, 1997

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN II 5%

> DLT >	ABBOTT	5%	N19438 002
> DLT >			APR 03, 1986
> ADD >	@	5%	N19438 002
> ADD >			APR 03, 1986

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 004 NOV 07, 1988
@	5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML	N19683 004 NOV 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 002 MAR 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 005 MAR 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML	N20678 001 MAR 26, 1997

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML	N20678 009 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML — N20678 011 MAR 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML — N20678 012 MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML — N20678 008 MAR 26, 1997

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 016 MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 017 MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 018 MAR 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 019 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE — 5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML — N20678 021 MAR 26, 1997

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLIN

AP + SEARLE — 25MG/ML — N87243 001 MAY 24, 1982

@ — 25MG/ML — N87243 001 MAY 24, 1982

AMINOPHYLLINE

AP ELKINS SINN — 25MG/ML — N87239 001

AP + — 25MG/ML — N87239 001

TABLET; ORAL

AMINOPHYLLINE

BD HALSEY — 100MG — N84674 001

@ — 100MG — N84674 001

TABLET, EXTENDED RELEASE; ORAL

PHYLLOCONTIN

+ PURDUE FREDERICK — 225MG — N86760 001

@ — 225MG — N86760 001

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

BP HALSEY — 10MG — N85923 001

BP — 50MG — N85925 001

BP — 75MG — N85926 001 MAY 20, 1983

BP — 100MG — N85927 001 MAY 20, 1983

@ — 10MG — N85923 001

@ — 50MG — N85925 001

@ — 75MG — N85926 001 MAY 20, 1983

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL
@ HALSEY 100MG N85927 001 MAY 20, 1983

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL
LIMBITROL
AB + ROCHE EQ 25MG BASE;10MG N16949 002
LIMBITROL DS
AB + ROCHE EQ 25MG BASE;10MG N16949 002

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
ETRAFON-A
BP SCHERING 10MG;4MG N14713 002
@ 10MG;4MG N14713 002

AMOXICILLIN

CAPSULE; ORAL
AMOXIL
AB + SMITHKLINE BEECHAM 250MG N50459 001
AB 250MG N62216 001
AB + 250MG N62216 001
AB + 500MG N50459 002
AB 500MG N62216 004
AB + 500MG N62216 004
@ 250MG N50459 001
@ 500MG N50459 002

POWDER FOR RECONSTITUTION; ORAL
AMOXIL
AB + SMITHKLINE BEECHAM 125MG/5ML N50460 001
AB 125MG/5ML N62226 001
AB + 125MG/5ML N62226 001
AB + 250MG/5ML N50460 002
AB + 50MG/ML N50460 005
AB 250MG/5ML N62226 002
AB + 250MG/5ML N62226 002
AB 50MG/ML N62226 005
AB + 50MG/ML N62226 005

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL
AMOXIL
@ SMITHKLINE BEECHAM 125MG/5ML N50460 001
@ 250MG/5ML N50460 002
@ 50MG/ML N50460 005
LAROTID
AB SMITHKLINE BEECHAM 50MG/ML N50460 006
@ 50MG/ML N50460 006

AMPHOTERICIN B

OINTMENT; TOPICAL
FUNGIZONE
+ APOTHECON 3% N50313 001
@ 3% N50313 001

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL
AGRYLIN
ROBERTS LABS EQ 0.5MG BASE N20333 001 MAR 14, 1997
+ EQ 1MG BASE N20333 002 MAR 14, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION
NORMIFLO
+ WYETH AYERST 5,000 UNITS/0.5ML N20227 002 MAY 23, 1997
+ 10,000 UNITS/0.5ML N20227 001 MAY 23, 1997

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL
+ SAVAGE LABS 650MG;50MG N88305 001 OCT 13, 1983
@ 650MG;50MG N88305 001 OCT 13, 1983

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

	CODOXY			
AA	HALSEY	**325MG;4.5MG;0.38MG**	**N87464 001**	**JUL 01, 1982**
	@	325MG;4.5MG;0.38MG	N87464 001	JUL 01, 1982

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

	ATRACURIUM BESYLATE			
AP	ABBOTT	**10MG/ML**	**N74633 001**	**DEC 23, 1996**
AP	FAULDING	**10MG/ML**	**N74740 001**	**MAR 28, 1997**
> ADD > **AP**	GENSIA	**10MG/ML**	**N74784 001**	**JUN 11, 1997**
> ADD >				
AP	OHMEDA	**10MG/ML**	**N74753 001**	**JAN 23, 1997**
	ATRACURIUM BESYLATE PRESERVATIVE FREE			
AP	ABBOTT	**10MG/ML**	**N74633 001**	**DEC 23, 1996**
AP		**10MG/ML**	**N74639 001**	**MAR 25, 1997**
AP	FAULDING	**10MG/ML**	**N74741 001**	**MAR 28, 1997**
AP	OHMEDA	**10MG/ML**	**N74768 001**	**JAN 23, 1997**
	TRACRIUM			
AP +	GLAXO WELLCOME	**10MG/ML**	**N18831 001**	**NOV 23, 1983**
AP +		**10MG/ML**	**N18831 002**	**JUN 20, 1985**
	TRACRIUM PRESERVATIVE FREE			
AP +	GLAXO WELLCOME	**10MG/ML**	**N18831 001**	**NOV 23, 1983**

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

	DIPHENOXYLATE HCL AND ATROPINE SULFATE			
AA	ROXANE	**0.025MG;2.5MG**	**N86057 001**	
	@	0.025MG;2.5MG	N86057 001	
	DIPHENOXYLATE HCL W/ ATROPINE SULFATE			
AA	KV PHARM	**0.025MG;2.5MG**	**N85659 001**	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

	DIPHENOXYLATE HCL W/ ATROPINE SULFATE			
	@ KV PHARM	0.025MG;2.5MG	N85659 001	

AZITHROMYCIN DIHYDRATE

INJECTABLE; INJECTION

	ZITHROMAX			
+	PFIZER	EQ 500MG BASE/VIAL	N50733 001	JAN 30, 1997

BACITRACIN

INJECTABLE; INJECTION

	BACIIM			
AP	PHARMA TEK	**50,000 UNITS/VIAL**	**N64153 001**	**MAY 09, 1997**
	BACITRACIN			
AP +	PHARMACIA AND UPJOHN	**50,000 UNITS/VIAL**	**N60733 002**	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

	CORTISPORIN			
+	GLAXO WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N50168 002	MAY 04, 1984
+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N50168 002	MAY 04, 1984

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

	BECONASE AQ			
> DLT > **BN**	GLAXO WELLCOME	EQ 0.042MG DIPROP/SPRAY	N19389 001	JUL 27, 1987
> DLT >				
> ADD > BN +		EQ 0.042MG DIPROP/SPRAY	N19389 001	JUL 27, 1987
> ADD >				

BETAMETHASONE VALERATE

CREAM; TOPICAL

		BETAMETHASONE VALERATE		
AB		FOUGERA	**EQ 0.1% BASE**	**N18861 001**
				AUG 31, 1983
AB	+		**EQ 0.1% BASE**	**N18861 001**
				AUG 31, 1983
		VALISONE		
AB	+	SCHERING	**EQ 0.1% BASE**	**N16322 001**
			EQ 0.01% BASE	N16322 002
	@		EQ 0.01% BASE	N16322 002
	@		EQ 0.1% BASE	N16322 001

LOTION; TOPICAL

		BETAMETHASONE VALERATE		
AB		FOUGERA	**EQ 0.1% BASE**	**N18866 001**
				AUG 31, 1983
AB	+		**EQ 0.1% BASE**	**N18866 001**
				AUG 31, 1983
		VALISONE		
AB	+	SCHERING	**EQ 0.1% BASE**	**N16932 001**
	@		EQ 0.1% BASE	N16932 001

OINTMENT; TOPICAL

		BETAMETHASONE VALERATE		
AB		FOUGERA	**EQ 0.1% BASE**	**N18865 001**
				AUG 31, 1983
AB	+		**EQ 0.1% BASE**	**N18865 001**
				AUG 31, 1983
		VALISONE		
AB	+	SCHERING	**EQ 0.1% BASE**	**N16740 001**
	@		EQ 0.1% BASE	N16740 001

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

		BETOPTIC PILO		
	+	ALCON	EQ 0.25% BASE;1.75%	N20619 001
				APR 17, 1997

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

		BLENOXANE		
AP	+	BRISTOL MYERS SQUIBB	**EQ 30 UNITS BASE/VIAL**	**N50443 002**
				SEP 07, 1995

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

		BLEOMYCIN SULFATE		
AP		PHARMACIA AND UPJOHN	**EQ 30 UNITS BASE/VIAL**	**N64084 002**
				JUN 01, 1996
	+		EQ 30 UNITS BASE/VIAL	N64084 002
				JUN 01, 1996

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

		BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER		
AP	+	BAXTER HLTHCARE	**200MG/100ML**	**N19837 002**
				APR 12, 1989
AP	+		**400MG/100ML**	**N19837 001**
				APR 12, 1989
	@		200MG/100ML	N19837 002
				APR 12, 1989
	@		400MG/100ML	N19837 001
				APR 12, 1989

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

		ALPHAGAN		
	+	ALLERGAN	0.5%	N20490 001
				MAR 13, 1997

BUDESONIDE

> DLT >
> DLT >
> ADD >
> ADD >

AEROSOL, METERED; NASAL

		RHINOCORT		
	+	ASTRA	0.05MG/INH	N20233 001
				FEB 14, 1994
	+		0.032MG/INH	N20233 001
				FEB 14, 1994

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

POWDER, METERED; INHALATION

		PULMICORT		
	+	ASTRA	0.16MG/INH	N20441 002
				JUN 24, 1997
	@		0.32MG/INH	N20441 003
				JUN 24, 1997

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		WELLBUTRIN			
	+	GLAXO WELLCOME	100MG	N20358 002	
				OCT 04, 1996	
	+		150MG	N20358 003	
				OCT 04, 1996	
		ZYBAN			
>DLT>		GLAXO WELLCOME	100MG	N20711 002	
>DLT>				MAY 14, 1997	
>DLT>			150MG	N20711 003	
>DLT>				MAY 14, 1997	
>ADD>	+		100MG	N20711 002	
>ADD>				MAY 14, 1997	
>ADD>	+		150MG	N20711 003	
>ADD>				MAY 14, 1997	

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

	FEMSTAT ONE			
+	SYNTEX	2%	N19881 001	
			FEB 07, 1997	

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE PRESERVATIVE FREE			
AP	ABBOTT	1MG/ML	N74620 001	
			JAN 22, 1997	
AP		1MG/ML	N74626 001	
			JAN 23, 1997	
AP		2MG/ML	N74620 002	
			JAN 22, 1997	
AP		2MG/ML	N74626 002	
			JAN 23, 1997	
	STADOL			
AP	+ APOTHECON	2MG/ML	N17857 004	
	STADOL PRESERVATIVE FREE			
AP	+ APOTHECON	1MG/ML	N17857 001	
AP	+	2MG/ML	N17857 002	

CALCIPOTRIENE

SOLUTION; TOPICAL

	DOVONEX		
+	BRISTOL MYERS SQUIBB 0.005%	N20611 001	
		MAR 03, 1997	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

	DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC			
	CONTAINER			
	MCGAW	4MG/100ML;4GM/100ML;6MG/100ML;		
>DLT>		120MG/100ML;62MG/100ML	N19634 002	
>DLT>			FEB 24, 1988	
>ADD>	@	4MG/100ML;4GM/100ML;6MG/100ML;		
>ADD>		120MG/100ML;62MG/100ML	N19634 002	
>ADD>			FEB 24, 1988	
	DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER			
AP	MCGAW	20MG/100ML;5GM/100ML;30MG/100ML;		
		600MG/100ML;310MG/100ML	N17510 001	
	@	20MG/100ML;5GM/100ML;30MG/100ML;		
		600MG/100ML;310MG/100ML	N17510 001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

	LACTATED RINGER'S IN PLASTIC CONTAINER		
AP	MCGAW	20MG/100ML;30MG/100ML;600MG/100ML;	
		310MG/100ML	N18023 001
	@	20MG/100ML;30MG/100ML;600MG/100ML;	
		310MG/100ML	N18023 001

CAPTOPRIL

TABLET; ORAL

	CAPOTEN		
AB	+ BRISTOL MYERS SQUIBB	25MG	N18343 002
AB		25MG	N18343 002
	CAPTOPRIL		
AB	EGIS PHARMS	12.5MG	N74748 004
			MAY 29, 1997
AB		25MG	N74748 002
			MAY 29, 1997

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	EGIS PHARMS	50MG	N74748 001 MAY 29, 1997
AB		100MG	N74748 003 MAY 29, 1997
AB	PUREPAC PHARM	12.5MG	N74640 001 MAR 31, 1997
AB		25MG	N74640 002 MAR 31, 1997
AB		50MG	N74640 003 MAR 31, 1997
AB		100MG	N74640 004 MAR 31, 1997
AB	STASON	12.5MG	N74677 004 MAY 30, 1997
AB		25MG	N74677 002 MAY 30, 1997
AB		50MG	N74677 001 MAY 30, 1997
AB		100MG	N74677 003 MAY 30, 1997
AB	WOCKHARDT	12.5MG	N74532 001 MAR 28, 1997
AB		25MG	N74532 002 MAR 28, 1997
AB		50MG	N74532 003 MAR 28, 1997
AB		100MG	N74532 004 MAR 28, 1997

CARBAMAZEPINE

TABLET; ORAL
EPITOL

AB	LEMMON	200MG	N70541 001 SEP 17, 1986
AB	TEVA	200MG	N70541 001 SEP 17, 1986

TABLET, CHEWABLE; ORAL
EPITOL

AB	LEMMON	100MG	N73524 001 JUL 29, 1992
AB	TEVA	100MG	N73524 001 JUL 29, 1992

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

AB	LEMMON	10MG;100MG	N73618 001 AUG 28, 1992
AB		25MG;100MG	N73589 001 AUG 28, 1992
AB		25MG;250MG	N73607 001 AUG 28, 1992
AB	TEVA	10MG;100MG	N73618 001 AUG 28, 1992
AB		25MG;100MG	N73589 001 AUG 28, 1992
AB		25MG;250MG	N73607 001 AUG 28, 1992

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA	AMIDE PHARM	350MG	N40188 001 MAR 07, 1997

CARVEDILOL

TABLET; ORAL
COREG

	SMITHKLINE BEECHAM	3.125MG	N20297 004 MAY 29, 1997

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	LEMMON	EQ 250MG BASE/VIAL	N63016 001 MAR 14, 1989
AP		EQ 500MG BASE/VIAL	N63016 002 MAR 14, 1989
AP		EQ 1GM BASE/VIAL	N63016 003 MAR 14, 1989
AP		EQ 5GM BASE/VIAL	N63018 001 MAR 05, 1990
AP		EQ 10GM BASE/VIAL	N63018 002 MAR 05, 1990

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM			
AP	TEVA	EQ 250MG BASE/VIAL	N63016 001	MAR 14, 1989
AP		EQ 500MG BASE/VIAL	N63016 002	MAR 14, 1989
AP		EQ 1GM BASE/VIAL	N63016 003	MAR 14, 1989
AP		EQ 5GM BASE/VIAL	N63018 001	MAR 05, 1990
AP		EQ 10GM BASE/VIAL	N63018 002	MAR 05, 1990

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL

		CEFTIN			
> DLT >	+	GLAXO WELLCOME	EQ 125MG BASE/5ML	N50672 001	JUN 30, 1994
> DLT >			EQ 125MG BASE/5ML	N50672 001	JUN 30, 1994
> ADD >					
> ADD >	+		EQ 250MG BASE/5ML	N50672 002	APR 29, 1997
> ADD >					

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	CEFUROXIME SODIUM			
AB	HANFORD GC	EQ 750MG BASE/VIAL	N64125 001	MAY 30, 1997
AP		EQ 1.5GM BASE/VIAL	N64125 002	MAY 30, 1997
AP		EQ 7.5GM BASE/VIAL	N64124 001	MAY 30, 1997
	KEFUROX			
AB	LILLY	EQ 750MG BASE/VIAL	N62591 001	JAN 10, 1986
AB		EQ 750MG BASE/VIAL	N62592 001	JAN 10, 1986
AP		EQ 750MG BASE/VIAL	N62591 001	JAN 10, 1986
AP		EQ 750MG BASE/VIAL	N62592 001	JAN 10, 1986
	ZINACEF			
AB	+ GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	ZINACEF			
AP	+ GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN			
AB	APOTHECON	EQ 250MG BASE	N62973 001	NOV 08, 1988
AB		EQ 500MG BASE	N62974 001	NOV 23, 1988
	@	EQ 250MG BASE	N62973 001	NOV 08, 1988
	@	EQ 500MG BASE	N62974 001	NOV 23, 1988
AB	PUREPAC PHARM	EQ 250MG BASE	N62809 001	APR 22, 1987
AB		EQ 500MG BASE	N62809 002	APR 22, 1987
	@	EQ 250MG BASE	N62809 001	APR 22, 1987
	@	EQ 500MG BASE	N62809 002	APR 22, 1987

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

	CEFADYL		
	APOTHECON	EQ 1GM BASE/VIAL	N62724 001 DEC 23, 1986
		EQ 2GM BASE/VIAL	N62724 002 DEC 23, 1986
	@	EQ 1GM BASE/VIAL	N62724 001 DEC 23, 1986
	@	EQ 2GM BASE/VIAL	N62724 002 DEC 23, 1986

> ADD > CERIVASTATIN SODIUM

TABLET; ORAL

	BAYCOL		
> ADD >	@ BAYER	0.05MG	N20740 001 JUN 26, 1997

> ADD > CERIVASTATIN SODIUM

> ADD > TABLET; ORAL
> ADD > BAYCOL
> ADD > @ BAYER 0.1MG N20740 002
> ADD > JUN 26, 1997
> ADD > 0.2MG N20740 003
> ADD > JUN 26, 1997
> ADD > + 0.3MG N20740 004
> ADD > JUN 26, 1997

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
OPHTHOCORT
\+ PARKE DAVIS 10MG/GM;5MG/GM; 10,000 UNITS/GM N50201 002
@ 10MG/GM;5MG/GM; 10,000 UNITS/GM N50201 002

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL
CHLOROMYCETIN PALMITATE
PARKE DAVIS EQ 150MG BASE/5ML N62301 001
@ EQ 150MG BASE/5ML N62301 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS
ROCHE 10MG N85481 001
@ 10MG N85481 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE
AT LEMMON **0.12%** **N74522 001**
DEC 15, 1995
AT TEVA **0.12%** **N74522 001**
DEC 15, 1995

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NESACAINE-MPF
AP + ASTRA **2%** **N09435 003**
AP + **2%** **N09435 006**
MAY 02, 1996
AP + **3%** **N09435 004**
AP + **3%** **N09435 007**
MAY 02, 1996
@ 2% N09435 003
@ 3% N09435 004

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
AA KV PHARM **4MG** **N87164 001**
@ 4MG N87164 001
KLOROMIN
AA HALSEY **4MG** **N83629 001**
@ 4MG N83629 001

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE
@ LEMMON 50MG N88651 001
MAY 30, 1985
@ TEVA 50MG N88651 001
MAY 30, 1985
THALITONE
BX HORUS THERAP 25MG N88051 001
NOV 12, 1982
\+ 15MG N19574 001
DEC 20, 1988
BX MONARCH PHARMS 25MG N19574 002
FEB 12, 1992
\+ 15MG N19574 001
DEC 20, 1988
@ 25MG N88051 001
NOV 12, 1982

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA	LEMMON	500MG	N89859 001 MAY 04, 1988
AA	TEVA	500MG	N89859 001 MAY 04, 1988

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	LEMMON	200MG	N74365 001 FEB 28, 1995
AB		300MG	N74365 002 FEB 28, 1995
AB		400MG	N74365 003 FEB 28, 1995
AB		800MG	N74365 004 FEB 28, 1995
AB	SIDMAK LABS NJ	200MG	N74568 001 FEB 27, 1997
AB		300MG	N74568 002 FEB 27, 1997
AB		400MG	N74568 003 FEB 27, 1997
AB		800MG	N74566 001 FEB 27, 1997
AB	TEVA	200MG	N74365 001 FEB 28, 1995
AB		300MG	N74365 002 FEB 28, 1995
AB		400MG	N74365 003 FEB 28, 1995
AB		800MG	N74365 004 FEB 28, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	SANOFI	EQ 300MG BASE/2ML	N74296 001 MAR 28, 1997
AP		EQ 300MG BASE/2ML	N74412 001 MAR 28, 1997

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL
CIMETIDINE HCL

AA	PHARM ASSOC	EQ 300MG BASE/5ML	N74553 001 JAN 27, 1997

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	LEMMON	EQ 0.5MG BASE/5ML	N73399 001 JUN 30, 1994
AA	TEVA	EQ 0.5MG BASE/5ML	N73399 001 JUN 30, 1994

TABLET; ORAL
CLEMASTINE FUMARATE

AB	LEMMON	2.68MG	N73283 001 JAN 31, 1992
	@	1.34MG	N73282 001 JAN 31, 1992
AB	TEVA	2.68MG	N73283 001 JAN 31, 1992
	@	1.34MG	N73282 001 JAN 31, 1992

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	QUAD PHARMS	EQ 150MG BASE/ML	N62795 001 DEC 21, 1987
	@	EQ 150MG BASE/ML	N62795 001 DEC 21, 1987

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

> ADD > AT	FOUGERA	EQ 1% BASE	N64159 001 JUN 05, 1997
> ADD > AT	LEMMON	EQ 1% BASE	N62930 001 JUN 28, 1989
AT	TEVA	EQ 1% BASE	N62930 001 JUN 28, 1989

CLOBETASOL PROPIONATE

CREAM; TOPICAL

		CORMAX		
	AB	HEALTHPOINT	0.05%	N74220 001 MAY 16, 1997

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

		CLOMIPRAMINE HCL		
> ADD >	AB	INVAMED	25MG	N74953 001 JUN 25, 1997
> ADD >	AB		50MG	N74953 002 JUN 25, 1997
> ADD >	AB		75MG	N74953 003 JUN 25, 1997
	AB	NOVOPHARM	25MG	N74849 001 APR 04, 1997
	AB		50MG	N74849 002 APR 04, 1997
	AB		75MG	N74849 003 APR 04, 1997

CLONAZEPAM

TABLET; ORAL

		KLONOPIN		
		+ ROCHE	0.125MG	N17533 005 APR 09, 1997
			0.25MG	N17533 006 APR 09, 1997

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

		CLORAZEPATE DIPOTASSIUM		
> DLT >	AB	PUREPAC PHARM	7.5MG	N71925 001 APR 25, 1988
> DLT >	AB		15MG	N71926 001 APR 25, 1988
> ADD >		@	7.5MG	N71925 001 APR 25, 1988
> ADD >		@	15MG	N71926 001 APR 25, 1988

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

		PHERAZINE W/ CODEINE		
AA		HALSEY	10MG/5ML;6.25MG/5ML	N88739 001 DEC 23, 1988
		@	10MG/5ML;6.25MG/5ML	N88739 001 DEC 23, 1988

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

	INTAL		
	+ FISONS	0.8MG/INH	N18887 001 DEC 05, 1985
	+ RHONE POULENC RORER	0.8MG/INH	N18887 001 DEC 05, 1985

CAPSULE; INHALATION

	INTAL		
	+ FISONS	20MG	N16990 001
	+ RHONE POULENC RORER	20MG	N16990 001

SOLUTION; INHALATION

		INTAL		
AN	+	FISONS	10MG/ML	N18596 001 MAY 28, 1982
AN	+	RHONE POULENC RORER	10MG/ML	N18596 001 MAY 28, 1982

SOLUTION/DROPS; OPHTHALMIC

	OPTICROM		
	@ FISONS	4%	N18155 001 OCT 03, 1984
	@ RHONE POULENC RORER	4%	N18155 001 OCT 03, 1984

SPRAY, METERED; NASAL

	NASALCROM		
	+ FISONS	5.2MG/SPRAY	N18306 001 MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION

	COBAVITE		
AP	STERIS	0.1MG/ML	N83013 001

CYANOCOBALAMIN

INJECTABLE; INJECTION

		COBAVITE		
AP		STERIS	**1MG/ML**	**N83064 001**
	@		0.1MG/ML	N83013 001
	@		1MG/ML	N83064 001
		CYANOCOBALAMIN		
AP		STERIS	**0.1MG/ML**	**N83120 001**
	@		0.1MG/ML	N83120 001

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A

		DICOPAC KIT		
> DLT >		AMERSHAM	N/A;N/A;N/A	N17406 001
> ADD >		MEDI PHYSICS	N/A;N/A;N/A	N17406 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		AK-PENTOLATE		
AT		AKORN	**1%**	**N85555 001**
	@		1%	N85555 001
		AKPENTOLATE		
AT		AKORN	**1%**	**N40164 001** JAN 13, 1997
AT			**2%**	**N40165 001** JAN 13, 1997
		CYCLOGYL		
AT	+	ALCON	**2%**	**N84108 001**

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

		CYCLOPHOSPHAMIDE		
AP		ASTA	**100MG/VIAL**	**N88371 001** JUL 03, 1986
AP			**200MG/VIAL**	**N88372 001** JUL 03, 1986
AP			**500MG/VIAL**	**N88373 001** JUL 03, 1986
AP			**1GM/VIAL**	**N88374 001** SEP 24, 1986
AP		ELKINS SINN	**100MG/VIAL**	**N88371 001** JUL 03, 1986

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

		CYCLOPHOSPHAMIDE		
AP		ELKINS SINN	**200MG/VIAL**	**N88372 001** JUL 03, 1986
AP			**500MG/VIAL**	**N88373 001** JUL 03, 1986
AP			**1GM/VIAL**	**N88374 001** SEP 24, 1986
		CYTOXAN		
AP	+	BRISTOL MYERS SQUIBB	**100MG/VIAL**	**N12142 001**
AP	+		**200MG/VIAL**	**N12142 002**
AP	+		**500MG/VIAL**	**N12142 003**
AP	+		**1GM/VIAL**	**N12142 004** AUG 30, 1982
AP	+		**2GM/VIAL**	**N12142 005** AUG 30, 1982
	@		100MG/VIAL	N12142 001
	@		200MG/VIAL	N12142 002
	@		500MG/VIAL	N12142 003
	@		1GM/VIAL	N12142 004 AUG 30, 1982
	@		2GM/VIAL	N12142 005 AUG 30, 1982

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

		CYPROHEPTADINE HCL		
AA		HALSEY	**4MG**	**N89057 001** JUL 03, 1986
	@		4MG	N89057 001 JUL 03, 1986

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		CERUBIDINE		
AP		RHONE POULENC RORER	**EQ 20MG BASE/VIAL**	**N61876 001**
	@		EQ 20MG BASE/VIAL	N61876 001
AP	+	WYETH AYERST	**EQ 20MG BASE/VIAL**	**N50484 001**
	@		EQ 20MG BASE/VIAL	N50484 001
		DAUNORUBICIN HCL		
AP		BEDFORD	**EQ 20MG BASE/VIAL**	**N64103 001** FEB 03, 1995

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL
\+ BEDFORD — EQ 20MG BASE/VIAL — N64103 001 FEB 03, 1995

DELAVIRDINE MESYLATE

TABLET; ORAL
RESCRIPTOR
\+ PHARMACIA AND UPJOHN — 100MG — N20705 001 APR 04, 1997

DESERPIDINE

> DLT > TABLET; ORAL
> DLT > HARMONYL
> DLT > \+ ABBOTT — 0.25MG — N10796 002
> ADD > @ — 0.25MG — N10796 002

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
AB SIDMAK LABS NJ — **100MG** — **N71803 001** MAY 29, 1997
AB — **150MG** — **N71804 001** MAY 29, 1997

DEXAMETHASONE

> DLT > GEL; TOPICAL
> DLT > DECADERM
> DLT > \+ MERCK SHARP DOHME — 0.1% — N13538 001
> ADD > @ — 0.1% — N13538 001

DEXAMETHASONE SODIUM PHOSPHATE

CREAM; TOPICAL
DECADRON
\+ MERCK SHARP DOHME — EQ 0.1% PHOSPHATE — N11983 002
@ — EQ 0.1% PHOSPHATE — N11983 002

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE
AP STERIS — **EQ 4MG PHOSPHATE/ML** — **N84355 001**
@ — EQ 4MG PHOSPHATE/ML — N84355 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW — 5GM/100ML;37MG/100ML — N19699 001 SEP 29, 1989
@ — 5GM/100ML;37MG/100ML — N19699 001 SEP 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW — **5GM/100ML;75MG/100ML** — **N19699 002 SEP 29, 1989**
@ — 5GM/100ML;75MG/100ML — N19699 002 SEP 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW — 5GM/100ML;110MG/100ML — N19699 003 SEP 29, 1989
@ — 5GM/100ML;110MG/100ML — N19699 003 SEP 29, 1989
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW — 5GM/100ML;220MG/100ML — N19699 005 SEP 29, 1989
@ — 5GM/100ML;220MG/100ML — N19699 005 SEP 29, 1989

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP MCGAW — **5GM/100ML;900MG/100ML** — **N18026 001**
@ — 5GM/100ML;900MG/100ML — N18026 001

DEXTROTHYROXINE SODIUM

TABLET; ORAL
CHOLOXIN
KNOLL PHARM — 1MG — N12302 005

DEXTROTHYROXINE SODIUM

>_DLT_>		TABLET; ORAL		
>_DLT_>		CHOLOXIN		
>_DLT_>		KNOLL PHARM	2MG	N12302 002
>_DLT_>	+		4MG	N12302 004
	@		1MG	N12302 005
>_ADD_>	@		2MG	N12302 002
>_ADD_>	@		4MG	N12302 004

DIAZEPAM

		INJECTABLE; INJECTION		
		DIAZEPAM		
	AP	STERIS	5MG/ML	N70912 001 AUG 28, 1986
	@		5MG/ML	N70912 001 AUG 28, 1986
		TABLET; ORAL		
		DIAZEPAM		
	AB	HALSEY	2MG	N70987 001 AUG 15, 1986
	AB		5MG	N70996 001 AUG 15, 1986
	AB		10MG	N70956 001 AUG 15, 1986
	@		2MG	N70987 001 AUG 15, 1986
	@		5MG	N70996 001 AUG 15, 1986
	@		10MG	N70956 001 AUG 15, 1986

DICLOFENAC SODIUM

		TABLET, DELAYED RELEASE; ORAL		
		DICLOFENAC SODIUM		
>_ADD_>	AB	COPLEY PHARM	25MG	N74459 001 JUN 25, 1997
>_ADD_>	AB		50MG	N74459 002 JUN 25, 1997
>_ADD_>	AB		75MG	N74459 003 JUN 25, 1997

DICYCLOMINE HYDROCHLORIDE

		CAPSULE; ORAL		
		DICYCLOMINE HCL		
	AB	WEST WARD	10MG	N40204 001 FEB 28, 1997

DIETHYLSTILBESTROL

		TABLET; ORAL		
		DIETHYLSTILBESTROL		
		LILLY	1MG	N04041 004
	+		5MG	N04041 005
	@		1MG	N04041 004
	@		5MG	N04041 005
		STILBESTROL		
		TABLICAPS	0.5MG	N83004 001
	@		0.5MG	N83004 001

DILTIAZEM HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE; ORAL		
		DILTIAZEM HCL		
	AB	MYLAN	60MG	N74910 001 MAY 02, 1997
	AB		90MG	N74910 002 MAY 02, 1997
	AB		120MG	N74910 003 MAY 02, 1997

DIMENHYDRINATE

		INJECTABLE; INJECTION		
		DIMENHYDRINATE		
	AP	ELKINS SINN	50MG/ML	N84767 001
	@		50MG/ML	N84767 001

DIPHENHYDRAMINE HYDROCHLORIDE

		INJECTABLE; INJECTION		
		DIPHENHYDRAMINE HCL		
	AP	STERIS	10MG/ML	N83533 001
	@		10MG/ML	N83533 001

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	CHELSEA LABS	50MG	N87160 001	JUN 07, 1996

DOXAZOSIN MESYLATE

TABLET; ORAL
CARDURA

	PFIZER	EQ 1MG BASE	N19668 001	NOV 02, 1990
+		EQ 8MG BASE	N19668 004	NOV 02, 1990
+		EQ 1MG BASE	N19668 001	NOV 02, 1990
		EQ 8MG BASE	N19668 004	NOV 02, 1990

ECONAZOLE NITRATE

CREAM; TOPICAL
SPECTAZOLE

+	J AND J	1%	N18751 001	DEC 23, 1982
+	JOHNSON RW	1%	N18751 001	DEC 23, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN

AT	STIEFEL	2%	N64127 001	FEB 14, 1997

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
ALESSE

+	WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997

TABLET; ORAL-28
ALESSE

	WYETH AYERST	0.02MG;0.1MG	N20683 002	MAR 27, 1997

ETODOLAC

CAPSULE; ORAL
ETODOLAC

AB	MYLAN	200MG	N74932 001	MAY 16, 1997
AB		300MG	N74932 002	MAY 16, 1997

LODINE

AB	WYETH AYERST	200MG	N18922 002	JAN 31, 1991
AB +		300MG	N18922 003	JAN 31, 1991

TABLET; ORAL
ETODOLAC

AB	ENDO LABS	400MG	N74841 001	JUN 27, 1997
AB	EON	400MG	N74903 001	APR 11, 1997
AB	INVAMED	400MG	N74846 001	FEB 28, 1997
AB	PUREPAC PHARM	400MG	N74819 001	FEB 28, 1997
AB	ROYCE LABS	400MG	N74892 001	APR 16, 1997
AB	ZENITH GOLDLINE	400MG	N74883 001	FEB 28, 1997

LODINE

AB	WYETH AYERST	400MG	N18922 004	JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE

AP	IMMUNEX	20MG/ML	N74513 001	MAR 14, 1996
AP	SUPERGEN	20MG/ML	N74513 001	MAR 14, 1996

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR

	@ 3M	50MG	N18830 004	AUG 23, 1988

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR
@ 3M 100MG N18830 001 OCT 31, 1985
@ 150MG N18830 003 JUN 03, 1988
50MG N18830 004 AUG 23, 1988
100MG N18830 001 OCT 31, 1985
+ 150MG N18830 003 JUN 03, 1988

FLUCONAZOLE

INJECTABLE; INJECTION
DIFLUCAN
+ PFIZER 200MG/100ML N19950 001 JAN 29, 1990

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ PFIZER 200MG/100ML N19950 003 SEP 29, 1992
@ 2MG/ML N19950 005 JUL 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%
+ PFIZER 200MG/100ML N19950 001 JAN 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+ PFIZER 200MG/100ML N19950 002 JAN 29, 1990
@ 2MG/ML N19950 004 JUL 08, 1994

FLUNISOLIDE

SPRAY, METERED; NASAL
NASALIDE
BX + DURA 0.025MG/SPRAY N18148 001
BX + SYNTEX 0.025MG/SPRAY N18148 001
NASAREL
BX + DURA 0.025MG/SPRAY N20409 001 MAR 08, 1995
BX + SYNTEX 0.025MG/SPRAY N20409 001 MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
SYNALAR
AT + MEDICIS 0.01% N12787 004
AT + 0.025% N12787 002
AT + 0.025% N12787 005
AT + SYNTEX 0.01% N12787 004
AT + 0.025% N12787 002
AT + 0.025% N12787 005
SYNALAR-HP
+ MEDICIS 0.2% N16161 002
+ SYNTEX 0.2% N16161 002

OINTMENT; TOPICAL
SYNALAR
AT + MEDICIS 0.025% N13960 001
AT + SYNTEX 0.025% N13960 001

SOLUTION; TOPICAL
SYNALAR
AT + MEDICIS 0.01% N15296 001
AT + SYNTEX 0.01% N15296 001

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-SYNALAR
+ MEDICIS 0.025%;EQ 3.5MG BASE/GM N60700 001
+ SYNTEX 0.025%;EQ 3.5MG BASE/GM N60700 001

FLUOCINONIDE

CREAM; TOPICAL
LIDEX
AB + MEDICIS 0.05% N16908 002
AB + SYNTEX 0.05% N16908 002
LIDEX-E
AB MEDICIS 0.05% N16908 003
AB SYNTEX 0.05% N16908 003

GEL; TOPICAL
LIDEX
AB + MEDICIS 0.05% N17373 001
AB + SYNTEX 0.05% N17373 001

OINTMENT; TOPICAL
LIDEX
AB + MEDICIS 0.05% N16909 002

FLUOCINONIDE

OINTMENT; TOPICAL

	LIDEX			
AB	+ SYNTEX	0.05%	N16909 002	

SOLUTION; TOPICAL

	LIDEX			
AT	+ MEDICIS	0.05%	N18849 001	APR 06, 1984
AT	+ SYNTEX	0.05%	N18849 001	APR 06, 1984

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

	FLURAZEPAM HCL			
AB	HALSEY	15MG	N71808 001	JAN 07, 1988
AB		30MG	N71809 001	JAN 07, 1988
	@	15MG	N71808 001	JAN 07, 1988
	@	30MG	N71809 001	JAN 07, 1988

FLURBIPROFEN

TABLET; ORAL

	FLURBIPROFEN			
AB	SIDMAK LABS NJ	50MG	N74647 001	APR 01, 1997
AB		100MG	N74647 002	APR 01, 1997
AB	WARNER CHILCOTT	100MG	N74560 002	MAY 16, 1997

FOLIC ACID

TABLET; ORAL

		FOLIC ACID			
> DLT >	AA	DANBURY PHARMA	1MG	N80680 001	
> ADD >	AA	+	1MG	N80680 001	
> DLT >		FOLVITE			
> DLT >	AA	+ LEDERLE	1MG	N05897 004	
> ADD >		@	1MG	N05897 004	

GLIPIZIDE

TABLET; ORAL

	GLIPIZIDE			
AB	SIDMAK LABS NJ	5MG	N74619 001	APR 04, 1997
AB		10MG	N74619 002	APR 04, 1997

GLUTETHIMIDE

TABLET; ORAL

	GLUTETHIMIDE			
AA	HALSEY	500MG	N89459 001	OCT 10, 1986
	@	500MG	N89459 001	OCT 10, 1986

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

		GRIFULVIN V			
> ADD >	+	J AND J	125MG/5ML	N50448 001	
			125MG/5ML	N62483 001	JAN 26, 1984
> DLT >	+	JOHNSON RW	125MG/5ML	N50448 001	
			125MG/5ML	N62483 001	JAN 26, 1984

TABLET; ORAL

		GRIFULVIN V			
> ADD >	AB	J AND J	250MG	N60618 002	
> ADD >	AB		250MG	N62279 002	
> ADD >	AB		500MG	N60618 003	
> ADD >	AB		500MG	N62279 003	
> ADD >			125MG	N60618 001	
> ADD >			125MG	N62279 001	
> DLT >	AB	JOHNSON RW	250MG	N60618 002	
> DLT >	AB		250MG	N62279 002	
> DLT >	AB		500MG	N60618 003	
> DLT >	AB		500MG	N62279 003	
> DLT >			125MG	N60618 001	
> DLT >			125MG	N62279 001	

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HCL

AB	AMIDE PHARM	**EQ 1MG BASE**	**N74673 001**	FEB 28, 1997
AB		**EQ 2MG BASE**	**N74673 002**	FEB 28, 1997
AB	MYLAN	**EQ 1MG BASE**	**N74796 001**	JAN 27, 1997
AB		**EQ 2MG BASE**	**N74796 002**	JAN 27, 1997
>ADD> **AB**	ROYCE LABS	**EQ 1MG BASE**	**N74762 001**	JUN 25, 1997
>ADD> **AB**		**EQ 2MG BASE**	**N74762 002**	JUN 25, 1997

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALDOL

+	JOHNSON RW	EQ 50MG BASE/ML	N18701 001	JAN 14, 1986
+		EQ 100MG BASE/ML	N18701 002	JAN 31, 1997

HALDOL DECANOATE 100

+	JOHNSON RW	EQ 100MG BASE/ML	N18701 002	OCT 31, 1989

HALDOL DECANOATE 50

+	JOHNSON RW	EQ 50MG BASE/ML	N18701 001	JAN 14, 1986

HEPARIN SODIUM

INJECTABLE; INJECTION
HEP FLUSH KIT IN PLASTIC CONTAINER

AP	FUJISAWA	**10 UNITS/ML**	**N17029 017**	DEC 05, 1985
AP		**100 UNITS/ML**	**N17029 018**	DEC 05, 1985
@		10 UNITS/ML	N17029 017	DEC 05, 1985
@		100 UNITS/ML	N17029 018	DEC 05, 1985

HEPARIN SODIUM

AP	FUJISAWA	**20,000 UNITS/ML**	**N17029 004**	
AP	STERIS	**1,000 UNITS/ML**	**N17064 002**	

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

@	STERIS	1,000 UNITS/ML	N17064 002

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
HYDROPANE

AA	HALSEY	**1.5MG/5ML;5MG/5ML**	**N88066 001**	JUN 28, 1985
@		1.5MG/5ML;5MG/5ML	N88066 001	JUN 28, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HCL

>ADD> **AP**	LUITPOLD	**20MG/ML**	**N40136 001**	JUN 30, 1997

TABLET; ORAL
HYDRALAZINE HCL

AA	HALSEY	**25MG**	**N89130 001**	JAN 15, 1986
AA		**100MG**	**N89178 001**	JAN 15, 1986
@		25MG	N89130 001	JAN 15, 1986
@		100MG	N89178 001	JAN 15, 1986

>ADD> HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

>ADD> TABLET; ORAL
>ADD> UNIRETIC

>ADD>	SCHWARZ PHARMA	12.5MG;7.5MG	N20729 001	JUN 27, 1997
>ADD> +		25MG;15MG	N20729 002	JUN 27, 1997

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

> ADD >	AB	GENEVA PHARMS	25MG;37.5MG	N74821 001	
> ADD >				JUN 05, 1997	

HYDROCORTISONE

CREAM; TOPICAL
DERMACORT

AT	MONARCH PHARMS	1%	N83011 002	
AT	SOLVAY	1%	N83011 002	
	PROCTOCORT			
AT	MONARCH PHARMS	1%	N83011 001	
AT	SOLVAY	1%	N83011 001	
	SYNACORT			
AT	MEDICIS	1%	N87458 001	
AT		2.5%	N87457 001	
@		0.5%	N87459 001	
AT	SYNTEX	1%	N87458 001	
AT		2.5%	N87457 001	
@		0.5%	N87459 001	

TABLET; ORAL
HYDROCORTISONE

> DLT >	BP	PUREPAC PHARM	10MG	N84247 003	
> DLT >				AUG 31, 1982	
> DLT >	BP		20MG	N84247 002	
> ADD >	@		10MG	N84247 003	
> ADD >				AUG 31, 1982	
> ADD >	@		20MG	N84247 002	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
CORTISPORIN

AT	+	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50479 001	
AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50479 001	
		OTOCORT			
AT		STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60730 002	
@			1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N60730 002	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC
OTOCORT

AT	STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62521 001 JUL 11, 1985
@		1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62521 001 JUL 11, 1985
	PEDIOTIC		
AT	GLAXO WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62822 001 SEP 29, 1987
AT	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62822 001 SEP 29, 1987

HYDROCORTISONE; UREA

CREAM; TOPICAL
ALPHADERM

@ BIOGLAN	1%;10%	N86008 001
@ VIVAN	1%;10%	N86008 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL
HEMSOL-HC

AT	ABLE	1%	N81274 001 JUN 19, 1992
+		1%	N81274 001 JUN 19, 1992
	HYDROCORTISONE ACETATE		
AT	+ PUREPAC PHARM	1%	N86052 001
@		1%	N86052 001

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE

BP	STERIS	25MG/ML	N83759 001
BP		50MG/ML	N83759 002
@		25MG/ML	N83759 001
@		50MG/ML	N83759 002

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL
CORTISPORIN
+ GLAXO WELLCOME — 0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM — N50218 001 AUG 09, 1985
+ MONARCH PHARMS — 0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM — N50218 001 AUG 09, 1985

HYDROCORTISONE BUTEPRATE

CREAM; TOPICAL
PANDEL
+ SAVAGE LABS — 0.1% — N20453 001 FEB 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
HYDROCORTISONE SODIUM SUCCINATE
AP ELKINS SINN — **EQ 1GM BASE/VIAL** — **N87569 001**
@ — EQ 1GM BASE/VIAL — N87569 001

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROMORPHONE HCL
>ADD< **AP** SANOFI WINTHROP — **10MG/ML** — **N74598 001**
>ADD< JUN 19, 1997

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL
AB HALSEY — **25MG** — **N89117 001** MAY 02, 1988
@ — 25MG — N89117 001 MAY 02, 1988
AB KV PHARM — **10MG** — **N87819 001** JUN 23, 1982
AB — **25MG** — **N87820 001** JUN 23, 1982

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL
AB KV PHARM — **50MG** — **N87821 001** JUN 23, 1982
AB — **100MG** — **N87822 001** JUN 23, 1982
@ — 10MG — N87819 001 JUN 23, 1982
@ — 25MG — N87820 001 JUN 23, 1982
@ — 50MG — N87821 001 JUN 23, 1982
@ — 100MG — N87822 001 JUN 23, 1982

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HY-PAM
AB EON — **EQ 25MG HCL** — **N87479 001**
HYDROXYZINE PAMOATE
AB EON — **EQ 25MG HCL** — **N87479 001**

IBUPROFEN

SUSPENSION; ORAL
IBU
BX KNOLL PHARM — **100MG/5ML** — **N19784 001** DEC 18, 1989
@ — 100MG/5ML — N19784 001 DEC 18, 1989

TABLET; ORAL
IBUPROFEN
AB PUREPAC PHARM — **800MG** — **N71964 001** FEB 01, 1988
@ — 800MG — N71964 001 FEB 01, 1988

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDAMYCIN PFS
+ PHARMACIA AND UPJOHN — 1MG/ML — N50734 001 FEB 17, 1997

IFOSFAMIDE

INJECTABLE; INJECTION
IFEX

+	BRISTOL MYERS SQUIBB	1GM/VIAL	N19763 001 DEC 30, 1988	>ADD<	>ADD<
+		3GM/VIAL	N19763 002 DEC 30, 1988		
@		1GM/VIAL	N19763 001 DEC 30, 1988		
@		3GM/VIAL	N19763 002 DEC 30, 1988		

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION
IFEX/MESNEX KIT

+	BRISTOL MYERS SQUIBB	1GM/VIAL;100MG/ML	N19763 003 OCT 10, 1992
+		3GM/VIAL;100MG/ML	N19763 004 OCT 10, 1992

IMIQUIMOD

CREAM; TOPICAL
ALDARA

+	3M	5%	N20723 001 FEB 27, 1997

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

AB	MYLAN	**1.25MG**	**N74461 002** MAR 26, 1997
AB	NOVOPHARM	**1.25MG**	**N74665 001** APR 04, 1997
AB		**2.5MG**	**N74665 002** APR 04, 1997

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION
INDIUM IN-111 OXYQUINOLINE

>DLT<	AMERSHAM	1mCi/ML	N19044 001 DEC 23, 1985	
>DLT<				

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION
INDIUM IN-111 OXYQUINOLINE

	MEDI PHYSICS	1mCi/ML	N19044 001 DEC 23, 1985

INDOCYANINE GREEN

INJECTABLE; INJECTION
CARDIO-GREEN

+	AKORN	25MG/VIAL	N11525 001
+		50MG/VIAL	N11525 002
+	BECTON DICKINSON	25MG/VIAL	N11525 001
+		50MG/VIAL	N11525 002

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-250

AP	FUJISAWA	**51%**	**N74679 001** APR 02, 1997

IOPAMIDOL-300

AP	ABBOTT	**61%**	**N74638 001** APR 30, 1997
AP	FUJISAWA	**61%**	**N74679 002** APR 02, 1997

IOPAMIDOL-300 IN PLASTIC CONTAINER

AP	ABBOTT	**61%**	**N74637 001** APR 03, 1997

IOPAMIDOL-370

AP	FUJISAWA	**76%**	**N74679 003** APR 02, 1997

ISOVUE-250

AP	+ BRACCO	**51%**	**N18735 007** JUL 06, 1992
AP	+	**51%**	**N20327 002** OCT 12, 1994

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ATROVENT

AN	+ BOEHRINGER INGELHEIM	**0.02%**	**N20228 001** SEP 29, 1993

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN	DEY	0.02%	N74755 001	JAN 10, 1997

ISONIAZID

SYRUP; ORAL
ISONIAZID

AA	CAROLINA MEDCL	50MG/5ML	N88235 001	NOV 10, 1983
+		50MG/5ML	N88235 001	NOV 10, 1983

LANIAZID

AA	LANNETT	50MG/5ML	N89243 001	FEB 03, 1986
@		50MG/5ML	N89243 001	FEB 03, 1986

TABLET; ORAL
ISONIAZID

> ADD >	AA	MIKART	100MG	N40090 001 JUN 26, 1997
> ADD >	AA		300MG	N40090 002 JUN 26, 1997

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION
ISOPROTERENOL HCL

> DLT >	BN	+	3M	0.12MG/INH	N10375 004
> ADD >		+		0.12MG/INH	N10375 004
> DLT >	BN		ALPHARMA	0.12MG/INH	N85904 001
> ADD >		@		0.12MG/INH	N85904 001

INJECTABLE; INJECTION
ISUPREL

> ADD >	AP	+	ABBOTT	0.2MG/ML	N10515 001
> DLT >	AP	+	SANOFI WINTHROP	0.2MG/ML	N10515 001

ITRACONAZOLE

SOLUTION; ORAL
SPORANOX

+	JANSSEN	10MG/ML	N20657 001	FEB 21, 1997

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

> ADD >	AP	ABBOTT	15MG/ML	N74801 001 JUN 05, 1997
> ADD >	AP		15MG/ML	N74802 001 JUN 05, 1997
> ADD >	AP		30MG/ML	N74801 002 JUN 05, 1997
> ADD >	AP		30MG/ML	N74802 002 JUN 05, 1997

TABLET; ORAL
KETOROLAC TROMETHAMINE

	AB	LEMMON	10MG	N74754 001 MAY 16, 1997
	AB	MYLAN	10MG	N74761 001 MAY 16, 1997
> ADD >	AB	ROXANE	10MG	N74790 001 JUN 26, 1997

TORADOL

	AB	+	SYNTEX	10MG	N19645 001 DEC 20, 1991

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL
PREVACID

TAP HOLDINGS	15MG	N20406 001	MAY 10, 1995
+	30MG	N20406 002	MAY 10, 1995

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID

TAP HOLDINGS	15MG	N20406 001	MAY 10, 1995
+	30MG	N20406 002	MAY 10, 1995

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

> ADD >	AP	+ ABBOTT	EQ 10MG BASE/ML	N40147 001		
> ADD >				JUN 25, 1997		
> ADD >	AP	+ BEDFORD	EQ 200MG BASE/VIAL	N40056 001		
> ADD >				MAY 23, 1995		
> DLT >		+	EQ 200MG BASE/VIAL	N40056 001		
> DLT >				MAY 23, 1995		
> ADD >	AP	GENSIA	EQ 350MG BASE/VIAL	N40174 001		
> ADD >				JUN 12, 1997		
> ADD >	AP	+ IMMUNEX	EQ 350MG BASE/VIAL	N08107 005	> DLT >	FUJISAWA 500MG/ML N19316 001
> ADD >				APR 05, 1989	> DLT >	SEP 08, 1986
	AP	PHARMACHEMIE	EQ 50MG BASE/VIAL	N89628 001	> ADD >	+ 500MG/ML N19316 001
				APR 17, 1997	> ADD >	SEP 08, 1986
	AP		EQ 100MG BASE/VIAL	N89915 001		MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
				APR 17, 1997	> DLT >	ABBOTT 1GM/100ML N20488 001
					> DLT >	JUL 11, 1995
					> ADD >	+ 1GM/100ML N20488 001
					> ADD >	JUL 11, 1995

TABLET; ORAL
LEUCOVORIN CALCIUM

	AB	PHARMACHEMIE	EQ 5MG BASE	N73099 001		MAGNESIUM SULFATE IN PLASTIC CONTAINER
				MAR 28, 1997	> DLT >	ABBOTT 4GM/100ML N20309 001
	AB		EQ 25MG BASE	N73101 001	> DLT >	JUN 24, 1994
				MAR 28, 1997	> DLT >	80MG/ML N20309 002
					> DLT >	JUN 24, 1994
					> ADD >	+ 4GM/100ML N20309 001
					> ADD >	JUN 24, 1994
					> ADD >	+ 80MG/ML N20309 002
					> ADD >	JUN 24, 1994

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT-3

+	TAP HOLDINGS	11.25MG/VIAL	N20708 001
			MAR 07, 1997

LUPRON DEPOT-4

+	TAP HOLDINGS	30MG/VIAL	N20517 002
			MAY 30, 1997

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHOBID

	SOLVAY	300MG	N18027 001
+		300MG	N18027 001

LORAZEPAM

SOLUTION; ORAL
LORAZEPAM

+	ROXANE	0.5MG/5ML	N74648 001
			MAR 18, 1997

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE

	FUJISAWA	500MG/ML	N19316 001
			SEP 08, 1986
+		500MG/ML	N19316 001
			SEP 08, 1986

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	ABBOTT	1GM/100ML	N20488 001
			JUL 11, 1995
+		1GM/100ML	N20488 001
			JUL 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	ABBOTT	4GM/100ML	N20309 001
			JUN 24, 1994
		80MG/ML	N20309 002
			JUN 24, 1994
+		4GM/100ML	N20309 001
			JUN 24, 1994
+		80MG/ML	N20309 002
			JUN 24, 1994

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HCL

AA	KV PHARM	12.5MG	N85524 001
AA		25MG	N85523 001
@		12.5MG	N85524 001
@		25MG	N85523 001
AA	VINTAGE PHARMS	12.5MG	N40179 001
			JAN 30, 1997
AA		25MG	N40179 002
			JAN 30, 1997

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

		HUMEGON			
	AB	+ ORGANON	**75 IU/VIAL;75 IU/VIAL**	**N20328 001**	
				SEP 01, 1994	
	AB		75 IU/VIAL;75 IU/VIAL	N20328 001	
				SEP 01, 1994	
	AB	+	**150 IU/VIAL;150 IU/VIAL**	**N20328 002**	
				SEP 01, 1994	
	AB		150 IU/VIAL;150 IU/VIAL	N20328 002	
				SEP 01, 1994	
>ADD<		**REPRONAL**			
>DLT<	**AB**	FERRING	**75 IU/VIAL;75 IU/VIAL**	**N73598 001**	
>DLT<				JAN 30, 1997	
>ADD<	**AB**		75 IU/VIAL;75 IU/VIAL	N73598 001	
>ADD<				JAN 30, 1997	
>DLT<	**AB**		**150 IU/VIAL;150 IU/VIAL**	**N73599 001**	
>DLT<				JAN 30, 1997	
>ADD<	**AB**		150 IU/VIAL;150 IU/VIAL	N73599 001	
>ADD<				JAN 30, 1997	

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	MEPERIDINE HCL			
AP	MALLINCKRODT	**10MG/ML**	**N40163 001**	
			MAY 12, 1997	

TABLET; ORAL

	MEPERIDINE HCL			
AA	ROXANE	**50MG**	**N40110 001**	
			MAR 12, 1997	
AA		**100MG**	**N40110 002**	
			MAR 12, 1997	
>ADD< **AA**	ROYCE LABS	**50MG**	**N40186 001**	
>ADD<			JUN 30, 1997	
>ADD< **AA**		**100MG**	**N40186 002**	
>ADD<			JUN 30, 1997	

METAPROTERENOL SULFATE

SYRUP; ORAL

	METAPROTERENOL SULFATE			
>DLT< **AA**	JVL	**10MG/5ML**	**N74702 001**	
>DLT<			MAR 24, 1997	

METAPROTERENOL SULFATE

SYRUP; ORAL

	METAPROTERENOL SULFATE			
AA	MORTON GROVE	**10MG/5ML**	**N71656 001**	
			OCT 13, 1987	
>ADD< **AA**		**10MG/5ML**	**N74702 001**	
>ADD<			MAR 24, 1997	
@		10MG/5ML	N71656 001	
			OCT 13, 1987	

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOPHAGE			
	BRISTOL MYERS SQUIBB	500MG	N20357 001	
			DEC 29, 1994	
+		850MG	N20357 002	
			DEC 29, 1994	
		500MG	N20357 001	
			MAR 03, 1995	
+		850MG	N20357 002	
			MAR 03, 1995	

METHACHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; INHALATION

PROVOCHOLINE			
	METHAPHARM	100MG/VIAL	N19193 001
			OCT 31, 1986
	ROCHE	100MG/VIAL	N19193 001
			OCT 31, 1986

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL			
AA	PUREPAC PHARM	**500MG**	**N85718 001**
AA		**750MG**	**N85718 002**
@		500MG	N85718 001
@		750MG	N85718 002

METHOTREXATE SODIUM

INJECTABLE; INJECTION
MEXATE-AQ PRESERVED

AP	BRISTOL MYERS	EQ 25MG BASE/ML	N89887 001 APR 14, 1989
	@ BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	N89887 001 APR 14, 1989

METHOXSALEN

CAPSULE; ORAL
OXSORALEN-ULTRA

	+ ICN	10MG	N19600 001 OCT 30, 1986

CAPSULE, LIQUID FILLED; ORAL
OXSORALEN-ULTRA

	+ ICN	10MG	N19600 001 OCT 30, 1986

METHYLDOPA

TABLET; ORAL
METHYLDOPA

AB	HALSEY	125MG	N71751 001 MAR 28, 1988
AB		250MG	N71752 001 MAR 28, 1988
	@	125MG	N71751 001 MAR 28, 1988
	@	250MG	N71752 001 MAR 28, 1988
AB	PUREPAC PHARM	125MG	N70749 001 FEB 07, 1986
AB		250MG	N70750 001 FEB 07, 1986
AB		500MG	N70452 001 FEB 07, 1986
	@	125MG	N70749 001 FEB 07, 1986
	@	250MG	N70750 001 FEB 07, 1986
	@	500MG	N70452 001 FEB 07, 1986

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	FAULDING	EQ 5MG BASE/ML	N71990 001 JAN 18, 1989
	@	EQ 5MG BASE/ML	N71990 001 JAN 18, 1989

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	MUTUAL PHARM	EQ 5MG BASE	N71536 002 JAN 16, 1997

METOLAZONE

TABLET; ORAL
MYKROX

	MEDEVA	0.5MG	N19532 001 OCT 30, 1987
	+	0.5MG	N19532 001 OCT 30, 1987

METRONIDAZOLE

GEL; VAGINAL
METROGEL-VAGINAL

	+ 3M	0.75%	N20208 001 AUG 17, 1992
	+ CURATEK	0.75%	N20208 001 AUG 17, 1992

INJECTABLE; INJECTION
METRONIDAZOLE

AP	STERIS	500MG/100ML	N70042 001 DEC 20, 1984
	@	500MG/100ML	N70042 001 DEC 20, 1984

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	WATSON LABS	150MG	N74711 001 FEB 26, 1997

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	WATSON LABS	**200MG**	**N74711 002**	FEB 26, 1997
AB		**250MG**	**N74711 003**	FEB 26, 1997

> ADD > MIBEFRADIL DIHYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > POSICOR

> ADD >	ROCHE	EQ 50MG BASE	N20689 001	JUN 20, 1997
> ADD >	+	EQ 100MG BASE	N20689 002	JUN 20, 1997

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM

> ADD >	+ J AND J	2%	N17494 001	
> DLT >	+ JOHNSON RW	2%	N17494 001	

LOTION; TOPICAL
MONISTAT-DERM

	@ J AND J	2%	N17739 001	
	@ JOHNSON RW	2%	N17739 001	

MIRTAZAPINE

TABLET; ORAL
REMERON

	+ ORGANON	30MG	N20415 002	JUN 14, 1996
		30MG	N20415 002	JUN 14, 1996
	+	45MG	N20415 003	MAR 17, 1997

MYCOPHENOLATE MOFETIL

TABLET; ORAL
CELLCEPT

> ADD >	+ SYNTEX	500MG	N50723 001	JUN 19, 1997

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB	ROYCE LABS	**EQ 0.5MG BASE; EQ 50MG BASE**	**N74736 001**	JAN 21, 1997

TALWIN NX

AB	+ SANOFI WINTHROP	**EQ 0.5MG BASE; EQ 50MG BASE**	**N18733 001**	DEC 16, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION
NANDROLONE DECANOATE

AO	STERIS	**50MG/ML**	**N87598 001**	OCT 06, 1983
AO		**100MG/ML**	**N87599 001**	OCT 06, 1983
	@	50MG/ML	N87598 001	OCT 06, 1983
	@	100MG/ML	N87599 001	OCT 06, 1983

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION
TILADE

	+ FISONS	1.75MG/INH	N19660 001	DEC 30, 1992
	+ RHONE POULENC RORER	1.75MG/INH	N19660 001	DEC 30, 1992

NELFINAVIR MESYLATE

POWDER FOR RECONSTITUTION; ORAL
VIRACEPT
+ AGOURON — EQ 50MG BASE/SCOOPFUL — N20778 001 MAR 14, 1997

TABLET; ORAL
VIRACEPT
+ AGOURON — EQ 250MG BASE — N20779 001 MAR 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX
AA PHARMA TEK — 100% — N61579 001
100% — N61579 001

NEOMYCIN SULFATE
AA PADDOCK — 100% — N62385 001 JUN 01, 1982

NIACIN

TABLET; ORAL
NIACIN
AA HALSEY — 500MG — N83453 001
@ — 500MG — N83453 001

NICOTINE

INHALANT; INHALATION
NICOTROL
+ PHARMACIA AND UPJOHN — 4MG/CARTRIDGE — N20714 001 MAY 02, 1997

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
LEVOPHED
> ADD > + ABBOTT — EQ 1MG BASE/ML — N07513 001
> DLT > + SANOFI WINTHROP — EQ 1MG BASE/ML — N07513 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL
> ADD > AB INVAMED — EQ 10MG BASE — N74835 001 JUN 30, 1997
> ADD > AB — EQ 25MG BASE — N74835 002 JUN 30, 1997
> ADD > AB — EQ 50MG BASE — N74835 003 JUN 30, 1997
> ADD > AB — EQ 75MG BASE — N74835 004 JUN 30, 1997

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL
ZOFRAN
+ GLAXO WELLCOME — EQ 4MG BASE/5ML — N20605 001 JAN 24, 1997

OXACILLIN SODIUM

CAPSULE; ORAL
BACTOCILL
AB SMITHKLINE BEECHAM — EQ 250MG BASE — N61336 001
AB + — EQ 250MG BASE — N61336 001

OXACILLIN SODIUM
AB APOTHECON — EQ 250MG BASE — N61450 002
AB + — EQ 500MG BASE — N61450 001
@ — EQ 250MG BASE — N61450 002
@ — EQ 500MG BASE — N61450 001

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
AA MORTON GROVE — 5MG/5ML — N74868 001 FEB 12, 1997

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN
+ PURDUE FREDERICK — 10MG — N20553 001 DEC 12, 1995

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

+	PURDUE FREDERICK	20MG	N20553 002	DEC 12, 1995
+		40MG	N20553 003	DEC 12, 1995
+	PURDUE PHARMA	10MG	N20553 001	DEC 12, 1995
+		20MG	N20553 002	DEC 12, 1995
+		40MG	N20553 003	DEC 12, 1995
+		80MG	N20553 004	JAN 06, 1997

OXYTOCIN

SOLUTION; NASAL
SYNTOCINON

+	NOVARTIS	40 USP UNITS/ML	N12285 001	
@		40 USP UNITS/ML	N12285 001	

PAROMOMYCIN SULFATE

CAPSULE; ORAL
HUMATIN

> ADD >	**AB**	+ PARKE DAVIS	**EQ 250MG BASE**	**N60521 001**	
> ADD >	**AB**		**EQ 250MG BASE**	**N62310 001**	
> ADD >		**PAROMOMYCIN SULFATE**			
> ADD >	**AB**	CARACO	**EQ 250MG BASE**	**N64171 001**	
> ADD >				JUN 30, 1997	

PAROXETINE HYDROCHLORIDE

> ADD > SUSPENSION; ORAL
> ADD > PAXIL

> ADD >	+	SMITHKLINE BEECHAM	EQ 10MG BASE/5ML	N20710 001
> ADD >				JUN 25, 1997

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

	RHONE POULENC RORER	2MG	N20184 001	DEC 30, 1993
		4MG	N20184 002	DEC 30, 1993
+		8MG	N20184 003	DEC 30, 1993
@		2MG	N20184 001	DEC 30, 1993
@		4MG	N20184 002	DEC 30, 1993
@		8MG	N20184 003	DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE

BC	GRAHAM DM	105MG	N87214 001	MAY 26, 1982
BC		105MG	N88020 001	AUG 16, 1982
BC		105MG	N88028 001	AUG 16, 1982
BC		105MG	N88062 001	SEP 13, 1982
BC		105MG	N88063 001	SEP 10, 1982
BC		105MG	N88111 001	OCT 18, 1982
@		105MG	N87214 001	MAY 26, 1982
@		105MG	N88020 001	AUG 16, 1982
@		105MG	N88028 001	AUG 16, 1982
@		105MG	N88062 001	SEP 13, 1982
@		105MG	N88063 001	SEP 10, 1982
@		105MG	N88111 001	OCT 18, 1982

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	INWOOD LABS	**35MG**	**N84740 001**

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	INWOOD LABS	35MG	N84741 001	
AA		35MG	N84742 001	
AA		35MG	N84743 001	
@		35MG	N84740 001	
@		35MG	N84741 001	
@		35MG	N84742 001	
@		35MG	N84743 001	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

> ADD > AA	AMIDE PHARM	30MG	N40227 001	
> ADD >			JUN 18, 1997	
> ADD > AA		37.5MG	N40228 001	
> ADD >			JUN 19, 1997	
AA	KING PHARMS	30MG	N40083 001	
			MAR 07, 1997	

TABLET; ORAL
PHENTERMINE HCL

AA	AMIDE PHARM	37.5MG	N40190 001	
			MAY 30, 1997	

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN

	PARKE DAVIS	30MG	N84349 001	
+		30MG	N84349 001	

PINDOLOL

TABLET; ORAL
PINDOLOL

> DLT > AB	LEMMON	5MG	N74123 001	
> DLT >			APR 17, 1997	
> DLT > AB		10MG	N74123 002	
> DLT >			APR 17, 1997	
> ADD > AB	TEVA	5MG	N74123 001	
> ADD >			APR 17, 1997	

PINDOLOL

TABLET; ORAL
PINDOLOL

> ADD > AB	TEVA	10MG	N74123 002	
> ADD			APR 17, 1997	

PODOFILOX

GEL; TOPICAL
CONDYLOX

+	OCLASSEN	0.5%	N20529 001	
			MAR 13, 1997	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
POLYTRIM

AT +	ALLERGAN	10,000 UNITS/ML; EQ 1MG BASE/ML	N50567 001	
			OCT 20, 1988	

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	BAUSCH AND LOMB	10,000 UNITS/ML; EQ 1MG BASE/ML	N64120 001	
			FEB 14, 1997	

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP +	ABBOTT	745MG/100ML	N20161 001	
			NOV 30, 1992	
AP +		14.9MG/ML	N20161 005	
			NOV 30, 1992	
@		745MG/100ML	N20161 001	
			NOV 30, 1992	
@		14.9MG/ML	N20161 005	
			NOV 30, 1992	
AP +	BAXTER HLTHCARE	746MG/100ML	N19904 005	
			DEC 17, 1990	
AP +		14.9MG/ML	N19904 001	
			DEC 26, 1989	
+		746MG/100ML	N19904 005	
			DEC 17, 1990	
+		14.9MG/ML	N19904 001	
			DEC 26, 1989	

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	+ ABBOTT	**1.49GM/100ML**	**N20161 002**	> DLT >		
			NOV 30, 1992	> DLT >		
	@	1.49GM/100ML	N20161 002	> ADD >		
			NOV 30, 1992	> ADD >		
AP	+ BAXTER HLTHCARE	**1.49GM/100ML**	**N19904 006**			
			DEC 17, 1990			
	+	1.49GM/100ML	N19904 006			
			DEC 17, 1990			

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

BX	PUREPAC PHARM	5MG	N80325 001
	@	5MG	N80325 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

	STERIS	25MG/ML	N83654 001
	@	25MG/ML	N83654 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PEDIAPRED

+	FISONS	EQ 5MG BASE/5ML	N19157 001
			MAY 28, 1986
+	MEDEVA	EQ 5MG BASE/5ML	N19157 001
			MAY 28, 1986

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	HALSEY	**5MG**	**N80300 001**
	@	5MG	N80300 001

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL

AB	INWOOD LABS	**500MG**	**N89840 001**
			MAR 06, 1989
	@	500MG	N89840 001
			MAR 06, 1989

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINE HCL

AP	STERIS	**1%**	**N83535 001**
AP		**2%**	**N83535 002**
	@	1%	N83535 001
	@	2%	N83535 002

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	STERIS	**EQ 5MG BASE/ML**	**N89605 001**
			JUL 08, 1987
	@	EQ 5MG BASE/ML	N89605 001
			JUL 08, 1987

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

AB	DURAMED	**EQ 5MG BASE**	**N40207 001**
			MAY 01, 1997
AB		**EQ 10MG BASE**	**N40207 002**
			MAY 01, 1997

PROGESTERONE

GEL; VAGINAL
CRINONE

+	COLUMBIA RES LABS	8%	N20756 001
			MAY 13, 1997

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	STERIS	25MG/ML	N83532 001	
AP		50MG/ML	N83532 002	
@		25MG/ML	N83532 001	
@		50MG/ML	N83532 002	

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

BP	PAR PHARM	15MG	N88377 001 DEC 08, 1983	
@		15MG	N88377 001 DEC 08, 1983	

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	ROXANE	40MG	N70518 001 JUL 07, 1986	
@		40MG	N70518 001 JUL 07, 1986	

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL

AP	STERIS	100MG/ML	N83760 001	
@		100MG/ML	N83760 001	> ADD >
				> ADD >

RESERPINE

TABLET; ORAL
RESERPINE

BP	PUREPAC PHARM	0.1MG	N80753 002	
BP		0.25MG	N80753 001	
@		0.1MG	N80753 002	
@		0.25MG	N80753 001	

RIFAMPIN

CAPSULE; ORAL
RIFAMPIN

AB	EON	300MG	N64150 001 MAY 28, 1997

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION
QUADRAMET

CYTOGEN	50mCi/ML	N20570 001 MAR 28, 1997

SECOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM SECOBARBITAL

AA	HALSEY	100MG	N84676 001
@		100MG	N84676 001

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL

AB	+ SOMERSET	5MG	N20647 001 MAY 15, 1996	
	+	5MG	N20647 001 MAY 15, 1996	

TABLET; ORAL
SELEGILINE HCL

AB	APOTEX	5MG	N74871 001 JUN 06, 1997	
AB	APOTHECON	5MG	N74672 001 APR 01, 1997	
AB	LEMMON	5MG	N74744 001 JAN 27, 1997	

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS

AP	ABBOTT	50MG/VIAL	N71555 001 NOV 16, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS
@ ABBOTT 50MG/VIAL N71555 001 NOV 16, 1987

SULFAMETHOXAZOLE

SUSPENSION; ORAL
GANTANOL
\+ ROCHE 500MG/5ML N13664 002
@ 500MG/5ML N13664 002

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
FLOMAX
\+ BOEHRINGER INGELHEIM 0.4MG N20579 001 APR 15, 1997

>ADD> TAZAROTENE

>ADD> GEL; TOPICAL
>ADD> TAZORAC
>ADD> ALLERGAN 0.05% N20600 001 JUN 13, 1997
>ADD>
>ADD> \+ 0.1% N20600 002 JUN 13, 1997
>ADD>

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
MDP-BRACCO
AP BRACCO N/A N18107 001
MDP-SQUIBB
AP BRACCO N/A N18107 001

TERFENADINE

TABLET; ORAL
SELDANE
AB \+ HOECHST MARION RSSL **60MG** N18949 001 MAY 08, 1985

TERFENADINE

TABLET; ORAL
TERFENADINE
AB BAKER NORTON **60MG** **N74475 001 JAN 03, 1997**

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
AB WARNER CHILCOTT **250MG** **N62300 001**
AB **500MG** **N62300 002**
@ 250MG N62300 001
@ 500MG N62300 002

INJECTABLE; INJECTION
ACHROMYCIN
AP \+ LEDERLE **250MG/VIAL** **N50273 002**
AP **500MG/VIAL** **N50273 003**
\+ 250MG/VIAL N50273 002
500MG/VIAL N50273 003

TETRACYN
AP PFIZER **250MG/VIAL** **N60096 001**
AP **500MG/VIAL** **N60096 002**
@ 250MG/VIAL N60096 001
@ 500MG/VIAL N60096 002

SUSPENSION; ORAL
TETRACYCLINE HCL
AB ALPHARMA **125MG/5ML** **N60633 001**
@ 125MG/5ML N60633 001
>DLT> **AB** PUREPAC PHARM **125MG/5ML** **N60291 001**
>ADD> @ 125MG/5ML N60291 001
TETRACYN
AB PFIPHARMECS **125MG/5ML** **N60095 001**
@ 125MG/5ML N60095 001

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201
AP DUPONT **1mCi/ML** **N17806 001**
AP \+ **1mCi/ML** N17806 001
AP MALLINCKRODT **1mCi/ML** **N18150 001**
AP \+ **1mCi/ML** N18150 001

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201

AP	+ MEDI PHYSICS	**1mCi/ML**	**N18110 002**	
			FEB 27, 1996	
		1mCi/ML	N18110 002	
			FEB 27, 1996	

THEOPHYLLINE

CAPSULE; ORAL
BRONKODYL

> DLT >				
> DLT >	BP	STERLING WINTHROP	100MG	N85264 001
> DLT >	BP		200MG	N85264 002
> ADD >	@		100MG	N85264 001
> ADD >	@		200MG	N85264 002

THEOPHYLLINE

BP	KV PHARM	100MG	N85263 001
BP		200MG	N85263 002
@		100MG	N85263 001
@		200MG	N85263 002

CAPSULE, EXTENDED RELEASE; ORAL
SOMOPHYLLIN-CRT

BC	GRAHAM DM	50MG	N87763 001
			FEB 27, 1985
BC		100MG	N87194 001
BC		200MG	N88382 001
			FEB 27, 1985
BC		250MG	N87193 001
BC		300MG	N88383 001
			FEB 27, 1985
@		50MG	N87763 001
			FEB 27, 1985
@		100MG	N87194 001
@		200MG	N88382 001
			FEB 27, 1985
@		250MG	N87193 001
@		300MG	N88383 001
			FEB 27, 1985

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL

AP	STERIS	**100MG/ML**	**N83534 001**

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL

	STERIS	200MG/ML	N83534 002
@		100MG/ML	N83534 001
@		200MG/ML	N83534 002

TILUDRONATE DISODIUM

TABLET; ORAL
SKELID

+	SANOFI	EQ 200MG BASE	N20707 001
			MAR 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC
BETIMOL

+	LEIRAS	EQ 0.25% BASE	N20439 001
			MAR 31, 1995
+		EQ 0.5% BASE	N20439 002
			MAR 31, 1995
+	OY STAR	EQ 0.25% BASE	N20439 001
			MAR 31, 1995
+		EQ 0.5% BASE	N20439 002
			MAR 31, 1995

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT	ADV REMEDIES	**EQ 0.25% BASE**	**N74465 001**
			MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74466 001**
			MAR 25, 1997
AT	AKORN	**EQ 0.25% BASE**	**N74515 001**
			MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74516 001**
			MAR 25, 1997
AT	BAUSCH AND LOMB	**EQ 0.25% BASE**	**N74778 001**
			MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74776 001**
			MAR 25, 1997
AT	FOUGERA	**EQ 0.25% BASE**	**N74667 001**
			MAR 25, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AT	FOUGERA	**EQ 0.5% BASE**	**N74668 001**	MAR 25, 1997
AT	PACIFIC PHARMA	**EQ 0.25% BASE**	**N74746 001**	MAR 25, 1997
AT		**EQ 0.5% BASE**	**N74747 001**	MAR 25, 1997

TIOCONAZOLE

OINTMENT; VAGINAL

VAGISTAT-1			
+	BRISTOL MYERS	6.5%	N19355 001 DEC 30, 1986

TOLMETIN SODIUM

TABLET; ORAL

	TOLMETIN SODIUM			
AB	BAKER NORTON	**EQ 600MG BASE**	**N74399 001**	MAR 28, 1996
> DLT > **AB**	LEMMON	**EQ 600MG BASE**	**N74729 001**	FEB 27, 1997
> ADD > @	TEVA	EQ 600MG BASE	N74729 001	FEB 27, 1997
AB	ZENITH GOLDLINE	**EQ 600MG BASE**	**N74399 001**	MAR 28, 1996

TOPIRAMATE

TABLET; ORAL

TOPAMAX			
@	JOHNSON RW	400MG	N20505 006 DEC 24, 1996

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON			
+	ORION	EQ 60MG BASE	N20497 001 MAY 29, 1997

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

	TRAZODONE HCL		
AB	LEMMON	**150MG**	**N74357 001** APR 30, 1997

TRETINOIN

CREAM; TOPICAL

	AVITA		
AB	PENEDERM	**0.025%**	**N20404 003** JAN 14, 1997
	RETIN-A		
AB +	J AND J	**0.025%**	**N19049 001** SEP 16, 1988

GEL; TOPICAL

RETIN-A MICRO			
+	ADV POLYMER	0.1%	N20475 001 FEB 07, 1997

TRIAMCINOLONE

TABLET; ORAL

TRIAMCINOLONE				
> DLT > **BP**	PUREPAC PHARM	**2MG**	**N84020 002**	
> DLT > **BP**		**4MG**	**N84020 003**	
> ADD > @		2MG	N84020 002	
> ADD > @		4MG	N84020 003	

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL

	TRIAMCINOLONE ACETONIDE		
AT	ALPHARMA	**0.1%**	**N87192 001** SEP 08, 1982
@		0.1%	N87192 001 SEP 08, 1982

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

	TRIAMCINOLONE DIACETATE		
BP	STERIS	**40MG/ML**	**N85529 001**

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
TRIAMCINOLONE DIACETATE
@ STERIS 40MG/ML N85529 001

TRIHEXYPHENIDYL HYDROCHLORIDE

> DLT > CAPSULE, EXTENDED RELEASE; ORAL
> DLT > ARTANE
> DLT > + LEDERLE 5MG N12947 001
> ADD > @ 5MG N12947 001

ELIXIR; ORAL
TRIHEXYPHENIDYL HCL
AA PHARM ASSOC 2MG/5ML N40177 001
APR 17, 1997

TRIMETHOPRIM

TABLET; ORAL
PROLOPRIM
> DLT > AB GLAXO WELLCOME 200MG N17943 003
> DLT > JUL 14, 1982
> ADD > AB + 200MG N17943 003
> ADD > JUL 14, 1982
> DLT > TRIMPEX 200
> DLT > AB + ROCHE 200MG N17952 002
> DLT > NOV 09, 1982
> ADD > @ 200MG N17952 002
> ADD > NOV 09, 1982

TROGLITAZONE

TABLET; ORAL
PRELAY
AB SANKYO 200MG N20719 001
JAN 29, 1997
AB 400MG N20719 002
JAN 29, 1997

REZULIN
AB PARKE DAVIS 200MG N20720 001
JAN 29, 1997
AB 400MG N20720 002
JAN 29, 1997

UREA C-14

CAPSULE; ORAL
PYTEST
+ TRI MED SPECLTS 1 uCi N20617 001
MAY 09, 1997

PYTEST KIT
+ TRI MED SPECLTS 1 uCi N20617 002
MAY 09, 1997

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ISOPTIN SR
AB + KNOLL PHARM 120MG N19152 003
MAR 06, 1991

VERAPAMIL HCL
AB MYLAN 120MG N74587 002
FEB 21, 1997

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCREX
AP + BRISTOL MYERS 5MG/VIAL N70867 001
JUL 12, 1988
@ BRISTOL MYERS SQUIBB 5MG/VIAL N70867 001
JUL 12, 1988

VINCRISTINE SULFATE
AP FAULDING 5MG/VIAL N71561 001
APR 11, 1988
+ 5MG/VIAL N71561 001
APR 11, 1988

WARFARIN SODIUM

TABLET; ORAL
COUMADIN
AB DUPONT MERCK 1MG N09218 022
MAR 01, 1990
AB + 2MG N09218 013
AB 2.5MG N09218 018
AB 4MG N09218 023
AUG 24, 1993
AB 5MG N09218 007
AB 7.5MG N09218 016

WARFARIN SODIUM

TABLET; ORAL

	COUMADIN		
AB	+ DUPONT MERCK	10MG	N09218 005
	WARFARIN SODIUM		
AB	BARR	1MG	N40145 001 MAR 26, 1997
AB		2MG	N40145 002 MAR 26, 1997
AB		2.5MG	N40145 003 MAR 26, 1997
AB		4MG	N40145 004 MAR 26, 1997
AB		5MG	N40145 005 MAR 26, 1997
AB		7.5MG	N40145 006 MAR 26, 1997
AB		10MG	N40145 007 MAR 26, 1997

ZINC ACETATE

CAPSULE; ORAL

	GALZIN		
	LEMMON	EQ 25MG ZINC	N20458 001 JAN 28, 1997
+		EQ 50MG ZINC	N20458 002 JAN 28, 1997

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV			
+ GRAHAM DM	12MG;75MG	N18793 001	APR 25, 1985
@	12MG;75MG	N18793 001	APR 25, 1985
COLD CAPSULE V			
GRAHAM DM	8MG;75MG	N18794 001	APR 23, 1985
@	8MG;75MG	N18794 001	APR 23, 1985

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE			
KV PHARM	12MG;120MG	N71455 001	MAR 01, 1989
@	12MG;120MG	N71455 001	MAR 01, 1989

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE			
LEMMON	1.34MG	N73282 002	DEC 03, 1992
TEVA	1.34MG	N73282 002	DEC 03, 1992

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK			
+ SCHERING PLOUGH	1%,200MG	N20526 002	JUL 29, 1996
GYNE-LOTRIMIN COMBINATION PACK			
+ SCHERING PLOUGH	1%,100MG	N20289 002	APR 26, 1993
MYCELEX-7 COMBINATION PACK			
BAYER	1%,100MG	N20389 002	JUN 23, 1994

CLOTRIMAZOLE

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK			
+ SCHERING PLOUGH	1%,200MG	N20526 002	JUL 29, 1996
GYNE-LOTRIMIN COMBINATION PACK			
+ SCHERING PLOUGH	1%,100MG	N20289 002	APR 26, 1993
MYCELEX-7 COMBINATION PACK			
BAYER	1%,100MG	N20389 002	JUN 23, 1994

SUPPOSITORY; VAGINAL

GYNE-LOTRIMIN			
+ SCHERING PLOUGH	100MG	N17717 002	NOV 30, 1990
GYNE-LOTRIMIN 3			
+ SCHERING PLOUGH	200MG	N20525 001	JUL 29, 1996
MYCELEX-7			
BAYER	100MG	N18182 002	DEC 26, 1991

TABLET; VAGINAL

GYNE-LOTRIMIN			
+ SCHERING PLOUGH	100MG	N17717 002	NOV 30, 1990
GYNE-LOTRIMIN 3			
+ SCHERING PLOUGH	200MG	N20525 001	JUL 29, 1996
MYCELEX-7			
BAYER	100MG	N18182 002	DEC 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL

NASALCROM			
+ PHARMACIA AND UPJOHN	5.2MG/SPRAY	N20463 001	JAN 03, 1997

IBUPROFEN

TABLET; ORAL

IBUPROFEN			
PUREPAC PHARM	200MG	N71122 001	OCT 03, 1986

IBUPROFEN

TABLET; ORAL
IBUPROFEN

	PUREPAC PHARM	200MG	N71664 001 FEB 03, 1987
	@	200MG	N71122 001 OCT 03, 1986
	@	200MG	N71664 001 FEB 03, 1987

JUNIOR STRENGTH MOTRIN

	MCNEIL	100MG	N20602 001 JUN 10, 1996
+		100MG	N20602 001 JUN 10, 1996

NUPRIN

> ADD >	@ MCNEIL	200MG	N19012 001 MAY 18, 1984
> ADD >	@	200MG	N19012 003 JUL 29, 1987
> DLT >	@ PHARMACIA AND UPJOHN	200MG	N19012 001 MAY 18, 1984
> DLT >	@	200MG	N19012 003 JUL 29, 1987

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
VELOSULIN BR HUMAN

+	NOVO NORDISK	100 UNITS/ML	N19450 001 MAY 30, 1986

VELOSULIN HUMAN

+	NOVO NORDISK	100 UNITS/ML	N19450 001 MAY 30, 1986

> ADD > LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL
IMODIUM ADVANCED

+	MCNEIL	2MG;125MG	N20606 001 JUN 26, 1996

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE

	PERRIGO	2%	N74760 001 MAY 15, 1997
	TARO	2%	N74444 001 JAN 13, 1997

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

	G AND W LABS	100MG	N74414 001 APR 30, 1997
+	PERRIGO	100MG	N74395 001 MAR 20, 1997

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)

	MORTON GROVE	2%	N74767 001 FEB 28, 1997

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

> ADD >	GRANUTEC	EQ 200MG BASE	N74635 001 JAN 13, 1997
> ADD >	INVAMED	EQ 200MG BASE	N74646 001 JAN 13, 1997
> DLT >	NOVOPHARM	EQ 200MG BASE	N74635 001 JAN 13, 1997
> DLT >	PERRIGO	EQ 200MG BASE	N74661 001 JAN 13, 1997
	PVT FORM	EQ 200MG BASE	N74789 001 FEB 27, 1997

PERMETHRIN

LOTION; TOPICAL
NIX

> ADD >	+ WARNER LAMBERT	1%	N19918 001 MAY 02, 1990
> DLT >	+ WARNER WELLCOME	1%	N19918 001 MAY 02, 1990

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

>_DLT_> CAPSULE, EXTENDED RELEASE; ORAL
>_DLT_> TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
>_DLT_> KV PHARM 120MG;5MG N71798 001
>_DLT_> MAR 16, 1989
>_ADD_> @ 120MG;5MG N71798 001
>_ADD_> MAR 16, 1989

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1
\+ BRISTOL MYERS SQUIBB 6.5% N20676 001
FEB 11, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 6/ JUNE '97

NO JUNE APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
January 1997 through June 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
15AU81 TN=	Treatment of primary pulmonary hypertension.	Lung Rx, Inc. 2 Davis Drive P.O. Box 13169 Research Triangle Park, NC 27709 DD=06/04/1997
8 Cyclopentyl 1,3-dipropylxanthine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard Suite 315 San Mateo, CA 94404 DD=03/24/1997
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623 DD=01/02/1997
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture TN= CYTOIMPLANT	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard Santa Fe Springs, CA 90670 DD=06/13/1997
Anagrelide TN= Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=01/27/1988 MA=03/14/1997

Orphan Product Designations and Approvals List
January 1997 through June 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
B2036-PEG TN= Trovert	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin, TX 78701 DD=06/24/1997
Beta alethine TN= Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Beta alethine TN= Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Coagulation Factor IX (recombinant) TN= BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=10/03/1994 MA=02/11/1997
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/28/1997
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/29/1997

Orphan Product Designations and Approvals List
January 1997 through June 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Dimethylsulfoxide TN=	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/15/1997
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=01/28/1997
Fampridine TN=	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 145 West 58th Sreet Suite 8J New York, NY 10019 DD=06/02/1997
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation P.O. Box 9322 One Mountain Road Framingham, MA 01701 DD=03/25/1997
Lepirudin TN= Refludan	Treatment of heparin-associated thrombocytopenia Type II.	Behringwerke AG P.O. Box 1140 D-35001 Marburg Germany, DD=02/13/1997
Levocarnitine TN= Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=04/07/1997

Orphan Product Designations and Approvals List
January 1997 through June 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
MART-1 adenoviral gene therapy for malignant melanoma TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=03/28/1997
Oxandrolone TN= Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corporation 70 Wood Avenue South Iselin, NJ 08830 DD=04/22/1997
Paclitaxel TN= Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=03/25/1997
Paclitaxel TN= Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard Miami, FL 33137 DD=04/15/1997
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 24209 Castillo Street, Suite 100 Santa Barbara, CA 93105 DD=02/18/1997
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington, DC 20008 DD=03/17/1997

Orphan Product Designations and Approvals List
January 1997 through June 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Porcine Sertoli cells TN= N-Graft	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Theracell, Inc. 50 Division Street Suite 503 Somerville, NJ 08876 DD=06/24/1997
Porfiromycin TN= Promycin	Treatment of cervical cancer.	Vion Pharmaceuticals, Inc. Four Science Park New Haven, CT 06511 DD=03/13/1997
Retroviral vector, R-GC and GC gene 1750 TN=	Treatment of Gaucher disease.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=05/06/1997
Suramin TN=	Treatment of metastatic hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=05/06/1997
Toremifene TN= Fareston	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 02101 ESPOO Finland, DD=09/19/1991 MA=05/29/1997
Zinc acetate TN= Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville, PA 19443 DD=11/06/1985 MA=01/28/1997

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 1997 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 17TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS

NEW INDICATION

I-177	TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS

PATENT USE CODE

U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINALTRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTRURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H.PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020059	001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
	020291	001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015		NC	OCT 24, 1999
	020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5225183	JUL 06, 2010		NP	AUG 15, 1999
				5439670	JUL 06, 2010			
				5605674	FEB 25, 2014			
	020560	001	ALENDRONATE SODIUM;FOSAMAX				I-185	APR 25, 2000
							I-187	APR 25, 2000
	020560	002	ALENDRONATE SODIUM;FOSAMAX				I-185	APR 25, 2000
							I-187	APR 25, 2000
	020560	003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		NS	APR 25, 2000
				4621077	NOV 04, 2003	U-114	I-185	APR 25, 2000
							I-187	APR 25, 2000
	020333	001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
							NCE	MAR 14, 2002
	020333	002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
							NCE	MAR 14, 2002
	020227	002	ARDEPARIN SODIUM;NORMIFLO				NCE	MAY 23, 2002
	020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH				NP	DEC 24, 1999
	020032	001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
>ADD>	020619	001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO	5635172	JUN 03, 2014	U-191	NC	APR 17, 2000
	020490	001	BRIMONIDINE TARTRATE;ALPHAGAN				NP	MAR 13, 2000
							NCE	SEP 06, 2001
>ADD>	020441	002	BUDESONIDE;PULMICORT	4907583	MAR 13, 2002			
>ADD>				4524769	JUN 25, 2002			
>ADD>				4668218	APR 11, 2006			
>ADD>	020441	003	BUDESONIDE;PULMICORT	4907583	MAR 13, 2002			
>ADD>				4524769	JUN 25, 2002			
>ADD>				4668218	APR 11, 2006			
	018644	002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	018644	003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
>ADD>	020711	002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
>ADD>				5427798	AUG 12, 2013			
>ADD>				RE33994	AUG 18, 2004			
>ADD>	020711	003	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013		NP	MAY 14, 2000
>ADD>				5427798	AUG 12, 2013			
>ADD>				RE33994	AUG 18, 2004			
	020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	JUN 04, 2008	U-177		
	019881	001	BUTOCONAZOLE NITRATE;FEMSTAT ONE	4078071	MAR 07, 1997		NP	FEB 07, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020664	001	CABERGOLINE;DOSTINEX					
>ADD>	020273	001	CALCIPOTRIENE;DOVONEX	4526892	JUL 02, 2002		NCE	DEC 23, 2001
>DLT>	020273	001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007		D-33	MAR 20, 2000
	020554	001	CALCIPOTRIENE;DOVONEX	4866048	SEP 12, 2006			
	020611	001	CALCIPOTRIENE;DOVONEX				NCE	DEC 29, 1998
				4866048	SEP 12, 2006		NDF	MAR 03, 2000
	019880	001	CARBOPLATIN;PARAPLATIN				NCE	DEC 29, 1998
	019880	002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880	003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
>ADD>	020740	001	CERIVASTATIN SODIUM;BAYCOL	4657927	APR 14, 2004	U-175		
>ADD>	020740	002	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
>ADD>	020740	003	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
>ADD>	020740	004	CERIVASTATIN SODIUM;BAYCOL				NCE	JUN 26, 2002
	019835	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC				NCE	JUN 26, 2002
	019835	002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	020346	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
>ADD>	019537	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4525358	JUN 25, 2007			
				5286754	FEB 15, 2011		I-188	JUN 03, 2000
>ADD>	019537	002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
>ADD>	019537	003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
>ADD>	019537	004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO				I-188	JUN 03, 2000
	019847	001	CIPROFLOXACIN;CIPRO				I-188	JUN 03, 2000
	019857	001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4705789	NOV 10, 2004		I-179	OCT 21, 1999
	019858	001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4808583	FEB 28, 2006		I-179	OCT 21, 1999
	017533	001	CLONAZEPAM;KLONOPIN	4705789	NOV 10, 2004		I-179	OCT 21, 1999
	017533	002	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	003	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	005	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	006	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	020463	001	CROMOLYN SODIUM;NASALCROM				I-184	APR 09, 2000
	020430	001	DANAPAROID SODIUM;ORGARAN				NP	JAN 03, 2000
	020705	001	DELAVIRDINE MESYLATE;RESCRIPTOR	5164377	OCT 03, 2010			
	020037	001	DICLOFENAC SODIUM;VOLTAREN	5563142	OCT 08, 2013		NCE	APR 04, 2002
				4960799	OCT 03, 2007			
	020154	002	DIDANOSINE;VIDEX	4829088	APR 14, 2007			
	020154	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020154	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020154	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
	020155	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020156	001	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
	018723	001	DIVALPROEX SODIUM;DEPAKOTE	5616566	AUG 29, 2006	U-180		
	018723	002	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	018723	003	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	019680	001	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	020668	001	ENALAPRIL MALEATE;LEXXEL	4988731	JAN 29, 2008		I-181	JUN 20, 1999
				4472380	SEP 18, 2001			
				4374829	DEC 30, 2001	U-3		
				4703038	OCT 07, 2005	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020444	001	EPOPROSTENOL SODIUM;FLOLAN	4335139	JUN 15, 1999			
>ADD>				4539333	SEP 03, 2002			
>ADD>				4883812	MAY 12, 2006	U-185		
>ADD>				4338325	JUL 06, 1999			
>ADD>	020444	002	EPOPROSTENOL SODIUM;FLOLAN	4539333	SEP 03, 2002			
>ADD>				4338325	JUL 06, 1999			
>ADD>				4883812	MAY 12, 2006	U-185		
>ADD>				4335139	JUN 15, 1999			
	020417	001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007		NP	DEC 03, 1999
				5006342	APR 09, 2008			
	019697	001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
	019697	002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
	018922	005	ETODOLAC;LODINE				I-24	JUN 28, 1999
	020410	001	FERUMOXSIL;GASTROMARK	5069216	MAY 09, 2006	U-171	NCE	DEC 06, 2001
				5219554	JUN 15, 2010			
				4827945	MAY 09, 2006	U-170		
				4951675	SEP 13, 2005	U-169		
				5055288	OCT 08, 2008			
				4695392	SEP 22, 2004			
				4695393	SEP 22, 2004			
				4770183	SEP 13, 2005	U-169		
	020038	001	FLUDARABINE PHOSPHATE;FLUDARA	4357324	FEB 24, 2003			
	020235	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86		
	020235	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86		
	020235	003	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008			
				4087544	JAN 16, 2000	U-86		
	020622	001	GLATIRAMER ACETATE;COPAXONE				ODE	DEC 20, 2003
	020329	001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
	020329	002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
>ADD>	020729	001	HYDROCHLOROTHIAZIDE;UNIRETIC	4344949	OCT 03, 2000			
>ADD>				4743450	FEB 24, 2007			
>ADD>	020729	002	HYDROCHLOROTHIAZIDE;UNIRETIC	4344949	OCT 03, 2000			
>ADD>				4743450	FEB 24, 2007			
	020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
	020723	001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2004	U-172	NCE	FEB 27, 2002
				5238944	AUG 24, 2010			
	040024	001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
	020083	001	ITRACONAZOLE;SPORANOX				I-178	DEC 06, 1999
	020657	001	ITRACONAZOLE;SPORANOX				NDF	FEB 21, 2000
	019927	001	KETOCONAZOLE;NIZORAL				I-186	MAY 30, 2000
>ADD>	019732	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	MAY 20, 2014			
>ADD>				5631021	MAY 20, 2014			
>ADD>				4954298	NOV 01, 2004			
>ADD>				5480656	JAN 02, 2013			
>ADD>	020011	001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	MAY 20, 2014			
>ADD>				5631021	MAY 20, 2014			
>ADD>				4954298	NOV 01, 2004			
>ADD>				5480656	JAN 02, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	MAY 20, 2014			
>ADD>			5631021	MAY 20, 2014			
>ADD>	020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	4677191	JUL 03, 2005			
>ADD>			4728721	MAY 01, 2006			
>ADD>			4849228	JUL 18, 2006			
>ADD>			5631020	MAY 20, 2014			
>ADD>			5631021	MAY 20, 2014			
>ADD>			4652411	NOV 01, 2004			
>ADD>			5476663	APR 17, 2007			
>ADD>			5480656	JAN 02, 2013			
>ADD>			5575987	NOV 19, 2013			
>ADD>			4917893	NOV 01, 2004			
>ADD>			4954298	NOV 01, 2004			
	020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5330767	NOV 01, 2004			
			4652411	NOV 01, 2004		NP	MAR 07, 2000
			4677191	JUL 03, 2005			
			4728721	MAY 01, 2006			
			4849228	JUL 18, 2006			
			4917893	NOV 01, 2004			
			4954298	NOV 01, 2004			
			5330767	NOV 01, 2004			
			5476663	APR 17, 2007			
			5480656	JAN 02, 2013			
			5575987	NOV 19, 2013			
			5631020	MAY 20, 2014			
			5631021	MAY 20, 2014			
>ADD>	020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	4652441	NOV 01, 2004			
>ADD>			5480656	JAN 02, 2013			
>ADD>			5631020	MAY 20, 2014			
>ADD>			5631021	MAY 20, 2014			
>ADD>	020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	4954298	NOV 01, 2004			
>ADD>			5480656	JAN 02, 2013			
>ADD>			5631020	MAY 20, 2014			
>ADD>			5631021	MAY 20, 2014			
>ADD>	020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	4954298	NOV 01, 2004			
>ADD>			5480656	JAN 02, 2013			
>ADD>			5631020	MAY 20, 2014			
>ADD>			5631021	MAY 20, 2014			
>ADD>	020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	4954298	NOV 01, 2004			
>ADD>			5480656	JAN 02, 2013			
>ADD>			5631020	MAY 20, 2014			
>ADD>			5631021	MAY 20, 2014			
>ADD>	020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	4954298	NOV 01, 2004			
>ADD>			5480656	JAN 02, 2013			
>ADD>			5631020	MAY 20, 2014			
>ADD>			5631021	MAY 20, 2014			
			4954298	NOV 01, 2004			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020606	001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED				NC	JUN 26, 2000
	020641	001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
	020704	001	LORATADINE;CLARITIN REDITABS	4282233	JUN 19, 2002	U-77	NCE	APR 12, 1998
				4659716	APR 21, 2004	U-142		
	020357	001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020357	002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
>ADD>	020689	001	MIBEFRADIL DIHYDROCHLORIDE;POSICOR				NCE	JUN 20, 2002
>ADD>	020689	002	MIBEFRADIL DIHYDROCHLORIDE;POSICOR				NCE	JUN 20, 2002
>ADD>	019297	001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	2222222	SEP 05, 1997			
>ADD>	020353	001	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
>ADD>	020353	002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
>ADD>	020353	003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
	019660	001	NEDOCROMIL SODIUM;TILADE				I-183	MAR 06, 2000
>ADD>	020778	001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NCE	MAR 14, 2002
>ADD>	020779	001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013		NCE	MAR 14, 2002
	020636	001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U-167	NCE	JUN 21, 2001
	020714	001	NICOTINE;NICOTROL				NP	MAY 02, 2000
	020592	001	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	002	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	003	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	004	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
>ADD>	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 24, 2014	U-184		
				4871865	OCT 03, 2006			
				4923892	MAY 08, 2007	U-174		
				5116863	MAY 26, 2009			
>ADD>	019810	001	OMEPRAZOLE;PRILOSEC	5629305	FEB 04, 2014	U-188		
				4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
>ADD>	019810	003	OMEPRAZOLE;PRILOSEC	5629305	FEB 04, 2014	U-188		
				4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
	020605	001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44		
				4695578	JUN 25, 2005	U-183		
				5578628	JUN 24, 2006	U-44		
				5641803	AUG 03, 2012			
>ADD>	020262	001	PACLITAXEL;TAXOL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-150	MAY 07, 1999
	020031	005	PAROXETINE HYDROCHLORIDE;PAXIL	5114948	OCT 19, 2009			
	019385	001	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
	019385	002	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
	019385	003	PERGOLIDE MESYLATE;PERMAX	4271143	MAY 09, 1999			
	018796	001	PILOCARPINE HYDROCHLORIDE;PILOPINE HS	4680399	JUL 14, 2004		NDF	MAR 13, 2000
	020529	001	PODOFILOX;CONDYLOX	5057616	OCT 15, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020756	001	PROGESTERONE;CRINONE					
	019627	002	PROPOFOL;DIPRIVAN				NP	MAY 13, 2000
>ADD>	020559	001	RANITIDINE BISMUTH CITRATE;TRITEC				NP	JUN 11, 1999
	020272	001	RISPERIDONE;RISPERDAL	5629297	MAY 13, 2014	U-186		
	020272	002	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	003	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	004	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020588	001	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
				5453425	JUN 11, 2014			
>ADD>	020659	001	RITONAVIR;NORVIR	5616587	JUN 11, 2014			
>ADD>	020680	001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U-190		
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5635523	JUN 03, 2014	U-190		
				5380922	JAN 10, 2012			
>ADD>	020570	001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	5225445	FEB 12, 2008	U-182		
>ADD>	020570	002	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
	019640	001	SOMATROPIN, BIOSYNTHETIC;HUMATROPE	4898724	FEB 06, 2007	U-187	NCE	MAR 28, 2002
							ODE	DEC 30, 2003
	019640	004	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
							ODE	DEC 30, 2003
	020168	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				I-182	DEC 30, 1999
							ODE	DEC 30, 2003
	020168	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				I-182	DEC 30, 1999
							ODE	DEC 30, 2003
	020579	001	TAMSULOSIN HYDROCHLORIDE;FLOMAX				I-182	DEC 30, 1999
				4868216	SEP 19, 2006	U-181	NCE	APR 15, 2002
				4731478	OCT 27, 2004			
				4703063	OCT 27, 2004			
				4772475	FEB 27, 2006			
>ADD>	020600	001	TAZAROTENE;TAZORAC					
>ADD>	020600	002	TAZAROTENE;TAZORAC				NCE	JUN 13, 2002
	019057	001	TERAZOSIN HYDROCHLORIDE;HYTRIN				NCE	JUN 13, 2002
				5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
	019057	002	TERAZOSIN HYDROCHLORIDE;HYTRIN			U-3		
				5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
	019057	003	TERAZOSIN HYDROCHLORIDE;HYTRIN			U-3		
				5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
	019057	004	TERAZOSIN HYDROCHLORIDE;HYTRIN			U-3		
				5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
	020347	001	TERAZOSIN HYDROCHLORIDE;HYTRIN			U-3		
				5294615	APR 29, 2013	U-3		
	020347	002	TERAZOSIN HYDROCHLORIDE;HYTRIN			U-165		
				5294615	APR 29, 2013	U-165		
	020347	003	TERAZOSIN HYDROCHLORIDE;HYTRIN			U-3		
				5294615	APR 29, 2013	U-165		
						U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020347	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020192	001	TERBINAFINE HYDROCHLORIDE;LAMISIL				I-180	JAN 21, 2000
	020707	001	TILUDRONATE DISODIUM;SKELID	4876248	OCT 24, 2006		NCE	MAR 07, 2002
				4980171	APR 06, 2009			
	020676	001	TIOCONAZOLE;VAGISTAT-1				NP	FEB 11, 2000
	020497	001	TOREMIFENE CITRATE;FARESTON				NCE	MAY 29, 2002
							ODE	MAY 29, 2004
>ADD>	020404	003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
				5045317	SEP 03, 2008	U-179		
	020475	001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NP	FEB 07, 2000
>ADD>	074374	001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL				I-189	JUN 17, 2000
	020326	001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4376858	MAY 09, 2004			
	020719	001	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
				5104888	AUG 28, 2004			
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
				5602133	SEP 15, 2013	U-173		
	020719	002	TROGLITAZONE;PRELAY	4572912	AUG 28, 2004		NCE	JAN 29, 2002
				5104888	AUG 28, 2004			
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
				5602133	SEP 15, 2013	U-173		
	020720	001	TROGLITAZONE;REZULIN	5457109	SEP 15, 2013	U-164	NCE	JAN 29, 2002
				5602133	SEP 15, 2013	U-173		
				5478852	SEP 15, 2013	U-163		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
	020720	002	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U-173	NCE	JAN 29, 2002
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
				5478852	SEP 15, 2013	U-163		
				5457109	SEP 15, 2013	U-164		
	020617	001	UREA C-14;PYTEST				NCE	MAY 09, 2002
	020617	002	UREA C-14;PYTEST KIT				NCE	MAY 09, 2002
	020665	001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
	020665	002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
>ADD>	020547	001	ZAFIRLUKAST;ACCOLATE	5612367	MAR 18, 2014	U-189		
>ADD>				5583152	AUG 22, 2006			
	020471	001	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
	020471	003	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
	020458	001	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
							ODE	JAN 28, 2004
	020458	002	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
							ODE	JAN 28, 2004

*U.S. Government Printing Office: 1997 - 417-599/40013

New 17th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7971

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/96)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____) _____
Daytime phone including area code

_____
Purchase Order No. (optional)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.